CN1297554C - Amido ether substituted imidazoquinolines - Google Patents
Amido ether substituted imidazoquinolines Download PDFInfo
- Publication number
- CN1297554C CN1297554C CNB018201679A CN01820167A CN1297554C CN 1297554 C CN1297554 C CN 1297554C CN B018201679 A CNB018201679 A CN B018201679A CN 01820167 A CN01820167 A CN 01820167A CN 1297554 C CN1297554 C CN 1297554C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- expression
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
在1-位上具有醚和酰胺官能团的咪唑并喹啉和四氢咪唑并喹啉化合物可以作为免疫应答调节剂，本发明化合物和组合物可以诱导细胞因子的生物合成，并可以治疗包括病毒性疾病和肿瘤疾病的许多种疾病。Imidazoquinoline and tetrahydroimidazoquinoline compounds with ether and amide functional groups at the 1-position can be used as immune response regulators, compounds and compositions of the present invention can induce the biosynthesis of cytokines, and can treat diseases including Many kinds of diseases and neoplastic diseases.
Description
Invention field
The present invention relates on the 1-position, have the imidazoquinolie compounds of ether and amide group functional group and relate to the pharmaceutical composition that contains described compound.The invention further relates to these compounds and comprise the purposes of virus disease and tumor disease as immunomodulator with the biosynthesizing of cytokine in the induced animal and treatment disease.
Background of the present invention
About the first piece of writing trustworthy account of 1H-imidazo [4,5-c] quinoline ring system, Backman etc. exist
J.Org.Chem.15, described among the 1278-1284 (1950) may be as 1-(6-methoxyl group-8-quinolyl)-2-methyl isophthalic acid H-imidazo [4, the 5-c] quinoline of antimalarial agent synthetic.Reported 1H-imidazo [4,5-c] quinoline synthetic of multiple replacement subsequently.For example, by people such as Jain,
J.Med. Chem.11, pp87-92 (1968) has synthesized 1-[2-(4-piperidyl) ethyl that can be used as anticonvulsive drug and cardiovascular drug]-1H-imidazo [4,5-c] quinoline compound.In addition, Baranov etc. are at Chem.Abs.85, in 94362 (1976), disclose also [4,5-c] quinoline compound of several 2-oxo-imidazoles, and Berenyi etc. exists
J.Heterocyclic Chem.18, among the 1537-1540 (1981), also [4,5-c] quinoline of some 2-oxo-imidazole is also disclosed.
Find that subsequently the derivative that some 1H-imidazo [4,5-c] quinoline-4-amine and 1-thereof and 2-replace can be used as antiviral agent, bronchodilator and immunomodulator.These are also specifically in U.S. Pat 4,689,338; 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; With 5,389,640 are described, and these documents all are incorporated herein by reference.
Interest to the imidazoquinoline ring system exists always.
Some has the substituent 1H-imidazo of the ether of containing [4,5-c] naphthyridine-4-amine on the 1-position, 1H-imidazo [4,5-c] pyridine-4-amine and 1H-imidazo [4,5-c] quinoline-4-amine is known compound, and in U.S. Pat .5,268,376; 5,389,640; 5,494,916 and WO 99/29693 in open.
Although make great efforts to differentiate compound always, still need to come the compound of induction of immunity response capacity by the biosynthesizing of the inducing cell factor or other mechanism as the immune response modifying factor.
The present invention's general introduction
But we have found that the biosynthetic compound of cytokine in one group of new induced animal.Therefore, the invention provides and on the 1-position, have also [4,5-c] quinoline-4-amine compound of the substituent imidazo of the ether of containing [4,5-c] quinoline-4-amine and imidazolidine.These compounds are suc as formula (I) with (II), and are as mentioned below more specifically.These compounds have the following formula structure:
Wherein X, R
1, R
2Described suc as formula (I) and formula (II) respectively with the definition of R.
Formula (I) and formula (II) compound can be because when using to animal as immune response modifier, and these compounds show the biosynthesizing of the inducing cell factor and regulate immunoreactive ability in addition.This makes this compound can be used for treating a series of diseases such as virus disease and the tumour that immunoreactive these variations is had response.
The present invention further provides and contained the pharmaceutical composition that compound is regulated in immune response, provide by using formula (I) to animal and formula (II) compound comes cytokine biosynthesizing in the induced animal, provide the treatment animal virus to infect, and/or the method for treatment tumor disease.
In addition, the present invention also provides the method for synthetic The compounds of this invention and the new intermediate that is adopted when synthesizing these compounds.
Detailed Description Of The Invention
As previously mentioned, we have found that some can biosynthesizing of the inducing cell factor and the compound of regulating the animal immune reaction.Described compound is as shown in the formula (I) and the compound (II).
The imidazoquinolie compounds of the present invention that has ether and amide functional group on the 1-position is by following formula (I) compound or pharmaceutically acceptable salt thereof:
Wherein:
X represents-CHR
5-,-CHR
5-alkyl-, perhaps-CHR
5-thiazolinyl-;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-alkyl;
-R
4-CR
3-Z-R
6-thiazolinyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-CR
3-Z-R
6-heteroaryl;
-R
4-CR
3-Z-R
6-heterocyclic radical;
-R
4-CR
3-Z-H；
-R
4-NR
7-CR
3-R
6-alkyl;
-R
4-NR
7-CR
3-R
6-thiazolinyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
-R
4-NR
7-CR
3-R
6-heterocyclic radical; With
-R
4-NR
7-CR
3-R
8；
Each Z is respectively-NR
5-,-O-or-S-;
R
2Expression is selected from following group:
-hydrogen;
-alkyl;
-thiazolinyl;
-aryl;
-heteroaryl;
-heterocyclic radical;
-alkyl-Y-alkyl;
-alkyl-Y-thiazolinyl;
-alkyl-Y-aryl; With
By one or more be selected from that following substituting group replaces-alkyl or-thiazolinyl:
-OH；
-halogen;
-N(R
5)
2；
-CO-N(R
5)
2；
-CO-C
1-10Alkyl;
-CO-O-C
1-10Alkyl;
-N
3；
-aryl;
-heteroaryl;
-heterocyclic radical;
-CO-aryl; With
-CO-heteroaryl;
Each R
3Expression=O or=S;
Each R
4Represent alkyl or thiazolinyl independently of one another, it can be interrupted by one or more-O-base;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6The expression key, alkyl, perhaps thiazolinyl, it can be interrupted by one or more-O-base;
R
7Expression H, C
1-10Alkyl, or aralkyl; Perhaps R
4And R
7Connect together and form ring;
R
8Expression H or C
1-10Alkyl; Perhaps R
7And R
8Connect together and form ring;
Each Y represents independently of one another-O-or-S (O)
0-2-;
N is 0-4; With
Each R represents to be selected from following group C independently of one another
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
The present invention is also included within has imidazolidine and the quinoline compound that contains ether and amide functional group on the 1-position.These compound or pharmaceutically acceptable salt thereofs are as shown in the formula shown in (II) or be its pharmacologically acceptable salt:
Wherein:
X represents-CHR
5-,-CHR
5-alkyl-, perhaps-CHR
5-thiazolinyl-;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-alkyl;
-R
4-CR
3-Z-R
6-thiazolinyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-CR
3-Z-R
6-heteroaryl;
-R
4-CR
3-Z-R
6-heterocyclic radical;
-R
4-CR
3-Z-H；
-R
4-NR
7-CR
3-R
6-alkyl;
-R
4-NR
7-CR
3-R
6-thiazolinyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
-R
4-NR
7-CR
3-R
6-heterocyclic radical;
-R
4-NR
7-CR
3-R
8；
Each Z independently is-NR
5-,-O-or-S-;
R
2Expression is selected from following group:
-hydrogen;
-alkyl;
-thiazolinyl;
-aryl;
-heteroaryl;
-heterocyclic radical;
-alkyl-Y-alkyl;
-alkyl-Y-thiazolinyl;
-alkyl-Y-aryl; With
By one or more be selected from that following substituting group replaces-alkyl or-thiazolinyl:
-OH；
-halogen;
-N(R
5)
2；
-CO-N(R
5)
2；
-CO-C
1-10Alkyl;
-CO-O-C
1-10Alkyl;
-N
3；
-aryl;
-heteroaryl;
-heterocyclic radical;
-CO-aryl; With
-CO-heteroaryl;
Each R
3Expression=O or=S;
Each R
4Represent alkyl or thiazolinyl independently of one another, it can be interrupted by one or more-O-base;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6The expression key, alkyl, perhaps thiazolinyl, it can be interrupted by one or more-O-base;
R
7Expression H, C
1-10Alkyl or aralkyl; Perhaps R
4And R
7Connect together and form ring;
R
8Expression H or C
1-10Alkyl; R
7And R
8Connect together and form ring;
Each Y represents independently of one another-O-or-S (O)
0-2-;
N is 0-4; With
Each R represents to be selected from following group C independently of one another
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
The preparation of compound
The compounds of this invention can be according to reaction process I preparation, R wherein, R
2, R
3, R
4, X, the definition of Z and n as mentioned above, and R
11Expression-R
6-alkyl ,-R
6-aryl ,-R
6-heteroaryl, or-R
6-heterocyclic radical, wherein R
6Definition as mentioned above.
In reaction process I step (1), adopt of 1H-imidazo [4, the 5-c] quinoline-1-base pure alkylation of formula XI halogenide with formula X, obtain 1H-imidazo shown in the formula XII [4,5-c] quinoline-1-base ether.As N, in the dinethylformamide, formula X alcohol obtains alkoxide with the sodium hydride reaction in suitable solvent.In addition, can phase-transfer catalyst for example the zephiran chloride trimethyl ammonium in the presence of, in the two-phase mixture of the inert solvent that comprises 50% aqueous sodium hydroxide solution and for example methylene dichloride, form alkoxide thereby add alcohol.Then alkoxide and halogenide are mixed, this reaction is at room temperature carried out.Many formula X compounds are known, referring to for example Gerster etc., and US4,689,338, other adopt known synthetic method to prepare easily, and referring to for example Gerster etc., US 5,605, and 899 and Gerster, US 5,175, and 296.Many formula XI halogenide can be bought and obtain, and other adopt known synthetic method to prepare easily.
In reaction process I step (2), adopt the oxygenant of conventional oxidable generation N-oxide compound, 1H-imidazo shown in the oxidation-type XII [4,5-c] quinoline-1-base ether obtains the 1H-imidazo shown in the formula XIII [4,5-c] quinoline-5N-oxide compound.Preferably, at room temperature use the chloroformic solution of 3-chloro-benzoyl hydroperoxide oxidation XII compound.
In reaction process I step (3), the 1H-imidazo shown in the ammonification formula XIII [4,5-c] quinoline-5N-oxide compound obtains the 1H-imidazo shown in the formula XIV [4,5-c] quinoline-4-amine, and it is the subgenus of formula I.Step (3) comprises that (i) makes formula XIII compound and acylating reagent react; (ii) make products therefrom and ammonification reagent react then.Step (3) (i) step comprises that the N-oxide compound that makes shown in the formula XIII reacts with acylating reagent, and suitable acylating reagent comprises alkyl-and aryl-alkylsulfonyl muriate (for example benzene sulfonyl chloride, methylsulfonyl chloride, Tosyl chloride).Aryl sulfonyl chloride is preferred.Tosyl chloride is most preferred.(ii) the step comprises and makes (i) step product and excessive ammonification reagent react, suitable ammonification reagent comprise ammonia (for example with the ammonium hydroxide form) and ammonium salt (for example volatile salt, bicarbonate of ammonia, ammonium phosphate) step (3) the.Ammonium hydroxide is preferred.Reaction preferably is dissolved in the N-oxide compound shown in the formula XIII in inert solvent such as the methylene dichloride, and adds ammonification reagent in the solution of gained, slowly adds acylating reagent then.Can separate with the method for routine and obtain product and pharmaceutically useful salt thereof.
In addition, step (3) can comprise that (i) makes N-oxide compound and the isocyanate reaction of formula XIII; The (ii) above-mentioned product of hydrolysis then.(i) step comprises and makes N-oxide compound and isocyanate reaction, and isocyano group wherein is connected on the carbonyl, and preferred isocyanic ester comprises the aroyl isocyanic ester of trichloroacetyl isocyanate and for example benzoyl isocyanic ester.Under substantially anhydrous condition, carry out the reaction of isocyanic ester and N-oxide compound, isocyanic ester is joined the N-oxide compound in the inert solvent solution in chloroform or the methylene dichloride for example.Step (ii) comprises the hydrolysis of step (i) product.Can adopt known traditional method for example choose wantonly catalyzer for example alkali metal hydroxide or rudimentary alkoxide in the presence of, in water or low-grade alkane alcohol, heat and be hydrolyzed.Can separate with the method for routine and obtain product and pharmaceutically useful salt thereof.
Reacting flow chart I
Can prepare The compounds of this invention according to reacting flow chart II, R wherein, R
2, R
4, R
7, R
11, the definition of X and n as above, BOC is a tert-butoxycarbonyl.
In reaction process II step (1), the amino in the formula XV amino alcohol is protected by tert-butoxycarbonyl.In the presence of alkali such as sodium hydroxide, handle the tetrahydrofuran solution of amino alcohol with the tert-Butyl dicarbonate (di-tert-butyl dicarbonatc) that contracts.Many formula XV amino alcohols are to obtain from market, and other can adopt known synthetic method preparation.
In reaction process II step (2), protected formula XVI amino alcohol is converted into the iodide shown in the formula XVII.Iodide are joined in the dichloromethane solution of triphenylphosphine and imidazoles; The dichloromethane solution that adds protected formula XVI amino alcohol then.This reaction can at room temperature be carried out.
In reaction process II step (3), adopt the iodide shown in the formula XVII with 1H-imidazo shown in the formula X [4,5-c] quinoline-pure alkylation of 1-base, obtain 1H-imidazo [4,5-c] quinoline-1-base ether of formula XVIII.The pure and mild sodium hydride of formula X forms alkoxide at suitable solvent such as N in the dinethylformamide.At room temperature iodide are joined then in this alkoxide solution, after interpolation is finished, elevated temperature (～100 ℃) stirred reaction mixture.
In reaction process II step (4), adopt the oxygenant of conventional oxidable generation N-oxide compound, 1H-imidazo shown in the oxidation-type XVIII [4,5-c] quinoline-1-base ether obtains the 1H-imidazo shown in the formula XIX [4,5-c] quinoline-5N-oxide compound.Preferably, at room temperature use the chloroformic solution of 3-chloro-benzoyl hydroperoxide oxidation XVIII compound.
In reaction process II step (5), the 1H-imidazo shown in the ammonification formula XIX [4,5-c] quinoline-5N-oxide compound obtains the 1H-imidazo shown in the formula XX [4,5-c] quinoline-4-amine.Step (5) comprises that (i) makes formula XIX compound and acylating reagent react; (ii) make products therefrom and ammonification reagent react then.Step (5) (i) step comprises that the N-oxide compound that makes shown in the formula XIX reacts with acylating reagent, and suitable acylating reagent comprises alkyl-and aryl-alkylsulfonyl muriate (for example benzene sulfonyl chloride, methylsulfonyl chloride, Tosyl chloride).Aryl sulfonyl chloride is preferred.Tosyl chloride is most preferred.(ii) the step comprises and makes (i) step product and excessive ammonification reagent react, suitable ammonification reagent comprise ammonia (for example with the ammonium hydroxide form) and ammonium salt (for example volatile salt, bicarbonate of ammonia, ammonium phosphate) step (5) the.Ammonium hydroxide is preferred.Reaction preferably is dissolved in inert solvent such as methylene dichloride or 1 with the N-oxide compound shown in the formula XIX, in the 2-ethylene dichloride, and heating if necessary, and in the solution of gained, add ammonification reagent, slowly add acylating reagent then.Optional elevated temperature (85-100 ℃) carries out this reaction in the seal-off pressure container.
In reaction process II step (6), obtain 1H-imidazo shown in the formula XXI [4,5-c] quinoline-4-amine by hydrolysis deprotection under the acidic conditions, preferred, under room temperature or mild heat condition, handle formula XX compound with spirit of salt/ethanol.
In reaction process II step (7), adopt traditional synthetic method that 1H-imidazo shown in the formula XXI [4,5-c] quinoline-4-amine is converted into formula XXII acid amides, it is the subgenus of formula I.For example formula XXI can with formula R
11The acyl chloride reaction of C (O) Cl.Reaction can be carried out in room temperature, will be dissolved in suitable solvent for example the acyl chlorides of methylene dichloride or 1-Methyl-2-Pyrrolidone join in the formula XXI compound solution.In addition, formula XXI compound can and R
11The acid-respons of COOH is reflected at room temperature, in the solvent of for example methylene dichloride or pyridine, and the coupling reagent that uses standard for example 1,3-bicyclohexane carbodiimide or 1[3-(dimethylamino) propyl group]-the 3-ethyl carbodiimide.Can separate with the method for routine and obtain product and pharmaceutically useful salt thereof.
Reaction process II
The compounds of this invention can be according to reaction process III preparation, R wherein, R
2, R
4, R
7, R
11, the definition of X and n as mentioned above and BOC be tert-butoxycarbonyl.
In reaction process III step (1), the amino in the formula XXIII amino alcohol is protected by tert-butoxycarbonyl.In the presence of alkali such as sodium hydroxide, handle the tetrahydrofuran solution of amino alcohol with the tert-Butyl dicarbonate that contracts.Many formula XXIII amino alcohols are to obtain from market, and other can adopt known synthetic method preparation.
In reaction process III step (2), protected formula XXIV amino alcohol is converted into the methanesulfonates shown in the formula XXV.In the presence of alkali such as triethylamine, handle the solution of formula XXIV compound in suitable solvent such as methylene dichloride with methylsulfonyl chloride.This reaction can be carried out (0 ℃) at low temperatures.
In reaction process III step (3a), formula XXV methanesulfonates is converted into formula XXVI trinitride.Sodiumazide is added to compounds X XV at suitable solvent such as N, in the solution of dinethylformamide.This reaction can be carried out under (80-100 ℃) under heating up.
In reaction process III step (3b), adopt formula Hal-R
7Shown in carboxylic acid halides with formula XXVI alkylation, obtain formula XXVII compound, work as R
7This step is omitted when being hydrogen.Compounds X XVI obtains a negatively charged ion with the sodium hydride reaction at suitable solvent such as N in the dinethylformamide, and is mixed with halogenide then.This reaction can at room temperature be carried out.
In reaction process III step (4), reduction-type XXVI or formula XXVII trinitride obtain the amine shown in the formula XXVIII.Preferably, conventional heterogeneous hydrogenation catalyst such as palladium/charcoal are adopted in this reaction.Be reflected in the Pa Er reactor and in suitable solvent such as methyl alcohol or Virahol, carry out easily.
In reaction process III step (5), make the amine reaction shown in 4-chloro-3-nitroquinoline shown in the formula XXIX and the formula XXVIII obtain the 3-nitroquinoline of formula XXX.This reaction can be added to the solution of formula XXIX compound in suitable solvent such as methylene dichloride with formula XXVIII amine and carry out in the presence of alkali such as triethylamine.The quinoline compound of many formula XXIX is the known known synthetic method preparation of maybe can adopting, referring to for example US 4,689,338, and the reference of wherein quoting from.
In reaction process III step (6), the 3-nitroquinoline shown in the reduction-type XXX is to the 3-quinolylamine of formula XXXI.Preferably should reaction adopt conventional heterogeneous hydrogenation catalyst such as platinum/charcoal.Be reflected in the Pa Er reactor and in suitable solvent such as toluene, carry out easily.
In reaction process III step (7), it is the 1H-imidazo shown in the XVIII [4,5-c] quinoline that the reaction of formula XXXI compound and carboxylic acid or its equivalent is obtained.The equivalent of suitable carboxylic acid comprises ortho ester and paraffinic acid 1,1-dialkoxy alkane ester.Select carboxylic acid or its equivalent to make it can in formula XVIII compound, obtain the R that needs
2Substituting group.For example, triethyl orthoformate can make wherein R
2The compound and the orthovaleric acid triethyl that are hydrogen can make wherein R
2It is the compound of butyl.This reaction can not have solvent or carry out in the presence of inert solvent such as toluene.Should fully heat any by-product alcohol or the water that generate in the dereaction to remove.Can choose wantonly and add catalyzer such as pyridine hydrochloride.
Perhaps, in reaction process III step (7), (i) make formula XXXI compound and formula R
2C (O) Cl or R
2The carboxylic acid halides reaction of C (O) Br, (ii) cyclisation then.In step (i), carboxylic acid halides is added to formula XXXI compound in the solution of inert solvent, inert solvent such as acetonitrile or methylene dichloride.Reaction can room temperature carry out or low temperature under carry out.Step (ii) in, in the presence of the alkali step (i) product is being heated in the alcohol solvent, preferably in the presence of excess of triethylamine in ethanol step of heating for reflux (i) product or it is heated with methanolic ammonia solution.
Step (8), (9), (10) and (11) can be according to reaction process II step (4), and (5), (6) and (7) described mode is carried out.
Reaction process III
The compounds of this invention can be according to reaction process IV preparation, R wherein, R
1, R
2, the definition of X and n as mentioned above.
In reaction process IV step (1), adopt of 4-amino-1H-imidazo [4, the 5-c] quinoline-1-base pure alkylation of formula XXXIII halogenide with formula XXXII, obtain 1H-imidazo shown in the formula I [4,5-c] quinoline-4-amine.As N, in the dinethylformamide, formula XXXII alcohol obtains alkoxide with the sodium hydride reaction in suitable solvent.Then halogenide is joined in the reaction mixture, can at room temperature or if desired under mild heat (～50 ℃) condition, carry out this reaction.Can separate with the method for routine and obtain product and pharmaceutically useful salt thereof.
Many formula XXXII compounds are known, referring to for example Gerster etc., and US4,689,338 and Gerster etc., US 5,605,899, and these disclosures are here as a reference; Other adopt known synthetic method to prepare easily, and for example referring to, Andre etc., US 5,578, and 727; Gerster, US 5,175, and 296; Nikolaides etc., US 5,395, and 937; With Gerster etc., US 5,741,908, and these disclosures here as a reference.Many formula XXXIII halogenide can be bought and obtain, and other adopt known synthetic method to prepare easily.
Reaction process IV
The compounds of this invention can be according to reaction process V preparation, R wherein, R
2, R
4, R
7, R
11, the definition of X and n as mentioned above.
In reaction process V step (1), 1H-imidazo [4, the 5-c] quinoline-4-amine shown in the reduction XXI obtains 6,7,8 shown in the formula XXXIV, 9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine.Preferably, reduction reaction is formula XXI compound is suspended in or is dissolved in the trifluoroacetic acid, adds the platinum oxide (IV) of catalytic amount, hydrogenation then.Be reflected in the Pa Er reactor and carry out easily.
In reaction process V step (2), according to carrying out, obtain 6,7,8 shown in the formula XXXV with the described same mode of reaction process II step (7), 9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine, it is the subgenus of formula II.The employing ordinary method can separated product or its pharmacologically acceptable salt.
Reaction process V
The compounds of this invention can be according to reaction process VI preparation, R wherein, R
1, R
2, the definition of X and n as mentioned above.
In reaction process VI, adopt formula XXXIII halogenide to make the 4-amino-6,7,8 shown in the formula XXXVI, 9-tetrahydrochysene-1H-imidazo [4, the 5-c] quinoline-pure alkylation of 1-base obtains shown in the formula II 6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine.As N, in the dinethylformamide, formula XXXVI alcohol obtains alkoxide with the sodium hydride reaction in suitable solvent.Then halogenide is joined in the reaction mixture, can at room temperature or if desired under mild heat (～50 ℃) condition, carry out this reaction.Can separate with the method for routine and obtain product and pharmaceutically useful salt thereof.
Shown in many formula XXXVI 6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline compound is known, referring to US 5,352,784 such as for example Nikolaides; Other adopt known synthetic method to prepare easily, for example referring to, Lindstrom US 5,693,811; These disclosures here as a reference.
Reaction process VI
The present invention also provides the available new intermediate compound of synthesis type (I) and formula (II) compound.The structure of these midbody compounds is described in detail hereinafter as shown in the formula shown in (III)-(V).
One group of midbody compound is suc as formula shown in (III) or be its pharmacologically acceptable salt.
Wherein:
X represents-CHR
5-,-CHR
5-alkyl-, perhaps-CHR
5-thiazolinyl-;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-alkyl;
-R
4-CR
3-Z-R
6-thiazolinyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-CR
3-Z-R
6-heteroaryl;
-R
4-CR
3-Z-R
6-heterocyclic radical;
-R
4-CR
3-Z-H；
-R
4-NR
7-CR
3-R
6-alkyl;
-R
4-NR
7-CR
3-R
6-thiazolinyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
-R
4-NR
7-CR
3-R
6-heterocyclic radical; With
-R
4-NR
7-CR
3-R
8
Each Z independently is-NR
5-,-O-, or-S-;
R
2Expression is selected from following group:
-hydrogen;
-alkyl;
-thiazolinyl;
-aryl;
-heteroaryl;
-heterocyclic radical;
-alkyl-Y-alkyl;
-alkyl-Y-thiazolinyl;
-alkyl-Y-aryl; With
By one or more be selected from that following substituting group replaces-alkyl or-thiazolinyl:
-OH；
-halogen;
-N(R
5)
2；
-CO-N(R
5)
2；
-CO-C
1-10Alkyl;
-CO-O-C
1-10Alkyl;
-N
3；
-aryl;
-heteroaryl;
-heterocyclic radical;
-CO-aryl; With
-CO-heteroaryl;
Each R
3Expression=O or=S;
Each R
4Represent alkyl or thiazolinyl independently of one another, it can be interrupted by one or more-O-base;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6Expression key, or expression alkyl or thiazolinyl, it can be interrupted by one or more-O-base;
R
7Expression H, C
1-10Alkyl or aralkyl, perhaps R
4And R
7Connect together and form ring;
R
8Expression H, C
1-10Alkyl; Perhaps R
7And R
8Connect together and form ring;
Each Y represents-O-or-S (O)
0-2-;
N is 0-4; With
Each R represents to be selected from following group: C independently of one another
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
Another group midbody compound is suc as formula shown in (IV) or be its pharmacologically acceptable salt:
Wherein:
X represents-CHR
5-,-CHR
5-alkyl-, perhaps-CHR
5-thiazolinyl-;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-alkyl;
-R
4-CR
3-Z-R
6-thiazolinyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-CR
3-Z-R
6-heteroaryl;
-R
4-CR
3-Z-R
6-heterocyclic radical;
-R
4-CR
3-Z-H；
-R
4-NR
5-CR
3-R
6-alkyl;
-R
4-NR
5-CR
3-R
6-thiazolinyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
-R
4-NR
7-CR
3-R
6-heterocyclic radical; With
-R
4-NR
5-CR
3-R
8；
Each Z represents-NR independently of one another
5-, or-O-;
Each R
3Expression=O or=S;
Each R
4Represent alkyl or thiazolinyl independently of one another, it can be interrupted by one or more-O-base;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6The expression key, alkyl, perhaps thiazolinyl, it can be interrupted by one or more-O-base;
R
7Expression H, C
1-10Alkyl, or aralkyl; Perhaps R
4And R
7Connect together and form ring;
R
8Expression H or C
1-10Alkyl; Perhaps R
4And R
7Connect together and form ring;
N is 0-4; With
Each R represents to be selected from following group: C independently of one another
1-10Alkyl, C
1-10Alkoxyl group, halogen and trifluoromethyl.
Another group midbody compound is shown in formula V or be its pharmacologically acceptable salt:
Wherein:
X represents-CHR
5-,-CHR
5-alkyl-, perhaps-CHR
5-thiazolinyl-;
R
2Expression is selected from following group:
-hydrogen;
-alkyl;
-thiazolinyl;
-aryl;
-heteroaryl;
-heterocyclic radical;
-alkyl-Y-alkyl;
-alkyl-Y-thiazolinyl;
-alkyl-Y-aryl; With
By one or more be selected from that following substituting group replaces-alkyl or-thiazolinyl:
-OH；
-halogen;
-N(R
5)
2；
-CO-N(R
5)
2；
-CO-C
1-10Alkyl;
-CO-O-C
1-10Alkyl;
-N
3；
-aryl;
-heteroaryl;
-heterocyclic radical;
-CO-aryl; With
-CO-heteroaryl;
Each R
4Represent alkyl or thiazolinyl independently of one another, it can be interrupted by one or more-O-base;
R
7Expression H, C
1-10Alkyl, or aralkyl, perhaps R
4And R
7Connect together and form ring;
Each Y represents independently of one another-O-or-S (O)
0-2-;
N is 0-4; With
Each R represents to be selected from following group: C independently of one another
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
Terminology used here " alkyl ", " thiazolinyl " and prefix " alkane " comprise that the straight or branched group also comprises cyclic group, i.e. cycloalkyl and cycloalkenyl group.Unless otherwise indicated, these groups are meant and contain 1-20 carbon atom, and thiazolinyl is meant the group that contains 2-20 carbon atom.Preferred group contains 10 carbon atoms at the most.Cyclic group can be monocycle or polycyclic and preferably contain 3-10 ring carbon atom.The example of cyclic group comprises cyclopropyl, cyclopropyl methyl, cyclopentyl, cyclohexyl and adamantyl.
In addition-alkyl in the X-group and alkenyl part can be unsubstituted or be selected from following substituting group and replace by one or more that these substituting groups are selected from: alkyl, thiazolinyl, aryl, heteroaryl, heterocyclic radical, aralkyl, heteroarylalkyl and heterocyclic radical alkyl.
The term here " alkylhalide group " is meant the group that is replaced by one or more halogens, comprises perfluoroalkyl.This definition also is suitable for containing the group of prefix " halogen ".The example of suitable alkylhalide group comprises: chloromethyl, trifluoromethyl etc.
The term here " aryl " comprises carbon aromatic ring or ring system.The example of aryl comprises phenyl, naphthyl, xenyl, fluorenyl or indenyl.Term " heteroaryl " be meant comprise contain at least one ring hetero atom (as O, S, aromatic ring N) or ring system.Suitable heteroaryl comprises furyl, thienyl, pyridyl, quinolyl, isoquinolyl, indyl, pseudoindoyl, triazolyl, pyrryl, tetrazyl, imidazolyl, pyrazolyl, azoles base, thiazolyl, benzofuryl, benzothienyl, carbazyl, benzoxazol base, pyrimidyl, benzimidazolyl-, quinoxalinyl, benzothiazolyl, naphthyridine base, different azoles base, isothiazolyl, purine radicals, quinazolyl etc.
" heterocyclic radical " be meant comprise contain at least one ring hetero atom (as O, S, non-aromatic ring N) or ring system and comprise the complete saturated of above-mentioned heteroaryl or the undersaturated derivative of part.The example of heterocyclic radical comprises: pyrrolidyl, tetrahydrofuran base, morpholinyl, thio-morpholinyl, piperidyl, piperazinyl, thiazolidyl, imidazolidyl and isothiazole alkyl etc.
The aryl here, heteroaryl and heterocyclic radical can be unsubstituted or be selected from following substituting group independently of one another and replace by one or more: alkyl; alkoxyl group, alkylthio, haloalkyl; halogenated alkoxy, halogenated alkylthio, halogen; nitro, hydroxyl, sulfydryl; cyano group, carboxyl, formyl radical; aryl, aryloxy, arylthio; alkoxy aryl, alkylthio-aryl, heteroaryl; heteroaryloxy, heteroarylthio, heteroaryl alkoxyl group; the heteroaryl alkylthio, amino, alkylamino; dialkyl amido, heterocyclic radical, Heterocyclylalkyl; alkyl-carbonyl, alkenyl carbonyl, alkoxy carbonyl; halogenated alkyl carbonyl, halo alkoxy carbonyl, alkylthio carbonyl (alkylthiocarbonyl); aryl carbonyl, heteroaryl carbonyl, aryloxycarbonyl; the heteroaryloxy carbonyl, arylthio carbonyl (arylthiocarbonyl), heteroarylthio carbonyl; alkyloyl oxygen base, alkyloyl sulfenyl, alkanoylamino; aroyl oxygen base, aroyl sulfenyl, aroylamino; the alkyl amine group alkylsulfonyl; alkyl sulphonyl, aryl sulfonyl, heteroarylsulfonyl; the aryl diazine; alkyl sulfonyl-amino, arlysulfonylamino, aryl alkylsulfonyl amino; alkyl-carbonyl-amino; alkenyl carbonyl amino, aryl-amino-carbonyl, aromatic yl alkyl carbonyl amino; the heteroaryl carbonylamino; the heteroarylalkyl carbonylamino, alkyl sulfonyl-amino, thiazolinyl sulfuryl amino; arlysulfonylamino; aryl alkylsulfonyl amino, heteroarylsulfonyl amino, heteroarylalkyl sulfuryl amino; alkyl amino-carbonyl amino; the alkenyl amino carbonylamino, aromatic yl aminocarbonyl amino, aryl-alkyl amino carbonylamino; the heteroaryl amino carbonylamino; the heteroarylalkyl amino carbonyl amino under the heterocyclic radical situation, is also represented oxo.If group is described to " replacement " or " optional replacement ", these groups can be replaced by one or more above-named substituting group so.
Usually some substituting group is preferred, for example preferred R
1Comprise :-R
4-CR
3-Z-R
6-alkyl ,-R
4-CR
3-Z-R
6-aryl, alkyl wherein and aryl can be unsubstituted or replace.R
3Preferably=O; R
4Preferred expression ethylidene and inferior normal-butyl; Z is preferred-NR
5-.Preferably there is not R substituting group (being n=0).Preferred R
2Comprise the alkyl (being methyl, ethyl, propyl group, sec.-propyl, normal-butyl, sec-butyl, isobutyl-and cyclopropyl methyl) that contains 1-4 carbon atom, methoxy ethyl and ethoxyl methyl.Concerning the group that replaces, the aryl of alkyl of Qu Daiing or replacement for example, preferred substituted comprises halogen, itrile group, methoxyl group, trifluoromethyl and trifluoromethoxy.If one or more above-mentioned preferred substituted exist, can any array mode in The compounds of this invention, exist.
The present invention includes the compound described herein that exists for any pharmaceutically useful form, comprise its isomer (as diastereomer and enantiomer), salt, solvate, polymorphic form, or the like.Especially, if a certain compound is optically active, the present invention also comprises the racemic mixture of the enantiomer and the enantiomer of each compound so.
Pharmaceutical composition and biological activity
Pharmaceutical composition of the present invention contains the above-claimed cpd of the present invention and the pharmaceutically acceptable carrier for the treatment of significant quantity.
Term " treatment significant quantity " is meant the amount of the The compounds of this invention that is enough to produce result of treatment, and the result of treatment here for example is meant and produces cytokine induction effect, anti-tumor activity and/or antiviral activity.Though, the concrete amount of the active compound that adopts in pharmaceutical composition of the present invention depends on the physico-chemical property of factors more known to a person of ordinary skill in the art such as compound, the character of carrier and the scheme of taking medicine that is adopted, to make the receptor can access dosage be the about 50mg/kg of about 100ng/kg-but the present composition should contain enough activeconstituentss, the compound of the preferred about 5mg/kg of about 10 μ g/kg-.Can adopt any regular dosage form such as tablet, lozenge, parenteral formulation, syrup, creme, paste, aerosol, through the skin patch, through mucous membrane patch etc.
When using, The compounds of this invention can be in treatment plan uses as the single therapy agent, also can with one or more other promoting agent drug combinations, these promoting agents comprise other immune response modifier, antiviral agent and antiseptic-germicide etc.
The evidence The compounds of this invention that carries out below shows can induce some cytokine to produce.These results show that The compounds of this invention can be used as immune response modifier and regulates immune response with multitude of different ways, make it can be used for multiple treatment of diseases.
Can induce the cytokine of generation to comprise Interferon, rabbit (α) (IFN-α) and/or tumour necrosis factor (α) (TNF-α) and some interleukin (IL) by using The compounds of this invention.Its biosynthesizing can comprise IFN-α by The compounds of this invention inductive cytokine, TNF-α, IL-1, IL-6, IL-10 and IL-12 and other various kinds of cell factor.At these on, above-mentioned cytokine and other cytokine can suppress virus and produce and growth of tumour cell, make these compounds can be used for treating virus disease and tumour.Therefore, the invention provides the biosynthetic method of cytokine in the induced animal, comprise The compounds of this invention or composition to animal administering therapeutic significant quantity.
Found that some The compounds of this invention can be under the situation of not supervening the conspicuous level inflammatory cytokine, preferentially induce the hematopoietic cell population that contains pDC2 cell (precursor dendritic cell-2 type), for example the expression of the IFN-α among the PBMC (blood monocyte on every side).
Except the ability that the inducing cell factor produces, The compounds of this invention also has influence on the others of innate immune system, for example can stimulate the activity of natural killer cell, and this effect may be based on the inducing action of cytokine.The compounds of this invention also can activating macrophage, and the secretion of macrophage-stimulating nitrogen oxide and the more generation of multiple cytokine.Further, The compounds of this invention can cause lymphocytic propagation of B-and differentiation.
The compounds of this invention is also influential to the acquired immune response.For example, though not be sure oing has direct effect and the T-cell cytokine is had direct inducing action the T-cell, but when using The compounds of this invention, the generation of 1 type helper cell (Th1) cytokine IFN-γ be can directly induce and 2 type helper cell (Th2) cytokine IL-4, the generation of IL-5 and IL-13 suppressed.Here actively be meant that these compounds are of value to these diseases of treatment when needs promote the Th1 reaction and/or suppress the situation of Th2 reaction.Consider that The compounds of this invention suppresses the immunoreactive ability of Th2, The compounds of this invention can be used for treating atopic disorder for example atopic dermatitis, asthma, allergy, allergic rhinitis; Systemic lupus erythematous; Also can be used as pair cell and regulate the vaccine adjuvant of immunity; With fungal disease that may be used for the treatment of recurrence and chlamydozoan disease.
The immune response regulating effect of The compounds of this invention makes it can be used for the treatment of many diseases.Because the ability that it has inducing cell factor IFN-α and/or TNF-α to produce, The compounds of this invention can be used in particular for treating virus disease and tumour.The immunoregulatory activity of The compounds of this invention shows that the treatable disease of The compounds of this invention for example includes but not limited to the disease that exemplifies below: virus disease comprises Genital warts; Common wart; Sole of the foot wart; Hepatitis B; Hepatitis C; I and II hsv disease; Molluscum contagiosum; Variola major; HIV; CMV; VZV; Rhinovirus; Adenovirus; Influenza; And parainfluenza; Intracutaneous tumorigenesis on last intracutaneous tumorigenesis such as the neck; Human papillomavirus (HPV) and relevant ND; Fungal disease for example, monilial infection disease, aspergillus infection disease and cryptococcal meningitis; Tumor disease, for example, rodent cancer, hairy cell leukemia, Kaposi sarcoma, renal cell carcinoma, squamous cell carcinoma, myelomatosis, multiple myeloma, melanoma, non_hodgkin lymphoma, the T-cell lymphoma of skin, and other cancer; Parasitosis is the Pneumocystis carinii disease for example, cryptosporidiosis, and Darling disease, toxoplasmosis, trypanosome is infected, and leishmaniasis; With for example tuberculosis and bird mycobacterium infection of infectation of bacteria.Can adopt other disease and the symptom of The compounds of this invention treatment to comprise: actinic keratosis; Eczema; Eosinophilia's disease; The thrombocythemia of the special property sent out; Leprosy; Multiple sclerosis; Door syndrome difficult to understand; Discoid lupus; Bowen disease; Class Bao grace papulosis; Alopecia areata; Suppress the formation of operation back keloid and other scar after the operation.In addition, these compounds can promote or stimulate the healing of wound, comprise chronic wounds.These compounds can also be used for the treatment of at for example transplant patient, and the immunity system that pair cell is regulated among tumour patient and patient HIV suppresses opportunistic infection and the tumour that the back occurs.
Effectively the amount of the biosynthetic compound of the inducing cell factor is meant and is enough to make one or more cells, for example monocyte, scavenger cell, dendritic cell and B-cell, produce one or more cytokines such as IFN-α, TNF-α, IL-1, IL-6, IL-10 and IL-12, the amount of these cytokines shows increase on its background level.Definite consumption depends on factor well known in the art, but should be contemplated to be about 50mg/kg at about 100ng/kg-, in the preferred about 5mg/kg dosage range of about 10 μ g/kg-.The present invention also provides the method for infection of treatment animal virus and tumor disease, comprises The compounds of this invention or composition to animal administering therapeutic significant quantity.The significant quantity of the treatment of compound or inhibition virus infection is meant the consumption of comparing the compound of for example viral damage of performance, virus loads, virus production rate and the mortality ratio that reduce one or more virus infectiones with the control group compound of not receiving treatment.Definite consumption depends on factor well known in the art, but should be contemplated to be about 50mg/kg at about 100ng/kg-, in the preferred about 5mg/kg dosage range of about 10 μ g/kg-.The treatment tumour significant quantity of compound is the consumption of instigating the compound that tumour size or tumor focus number dwindle.Same, definite consumption depends on factor well known in the art, but should be contemplated to be about 50mg/kg at about 100ng/kg-, in the preferred about 5mg/kg dosage range of about 10 μ g/kg-.
The present invention further provides following embodiment, it to be in order describing but not to be to limit the present invention by any way.
Some compounds adopt partly preparation property HPLC purifying in the following embodiments.Two kinds of different methods as described below have been adopted.
Method A
Method A uses the A-100 Gilson-6 that is equipped with 900 serial intelligence interfaces.Fraction is analyzed with LC-APCI/MS among the preparation property HPLC, and merges the trifluoroacetate that required fraction and freeze-drying obtain required compound.
Post: Microsorb C18 post, 21.4 * 250mm, granular size: 8 microns, 60 holes, flow velocity: 10mL/ minute; Took off 25 minutes from the suction of 2-95%B gradient, stopped 5 minutes at 95%B, wherein A=0.1% trifluoroacetic acid/water and B=0.1% trifluoroacetic acid/acetonitrile; Carry out the peak at 254nm and detect the collection of startup fraction.
Method B
This method has adopted the automatic purification system of Waters Fraction Lynx.Analyze partly fraction among the preparation property HPLC with MicromassLC-TOFMS, and merge the trifluoroacetate that required fraction and centrifugal evaporation obtain required compound.With
1H NMR spectrum is determined structure.
Post: Phenomenex Luna C18 (2), 10 * 50mm, granular size: 5 microns, 100 holes, flow velocity 25mL/ minute; Gradient is inhaled and to be taken off from 5-65%B 4 minutes, and 65-95%B is 0.1 minute then, keeps 0.4 minute at 95%B then, wherein A=0.05% trifluoroacetic acid/water and B=0.05% trifluoroacetic acid/acetonitrile; Selecting to start fraction by quality collects.
Embodiment 1
1-[2-(2-amino ethoxy) ethyl)]-2-butyl-1H-imidazo [4,5-c] quinoline-4-amine
Steps A
(29.0g 0.276mol) is cooled to 0 ℃ in (THF) of 180mL tetrahydrofuran (THF) solution, and handles with the 2N sodium hydroxide solution of 140mL with 2-(2-amino ethoxy) ethanol in the nitrogen atmosphere.In 1 hour, be added dropwise to one then in the solution under quick stirring and contract that (60.2g is 0.276mol) in the solution of 180mL THF for tert-Butyl dicarbonate.Making reaction mixture be warming to room temperature and continue then stirred 18 hours.Tetrahydrofuran (THF) is removed in decompression, and the aqueous slurry of gained is transferred to pH is 3 by adding 150mL 1M sulphuric acid soln.(300mL 100mL) extracts, and the organic layer of water (2X) and salt water washing merging with ethyl acetate.Obtain 2-(2-hydroxyl-oxethyl) the ethyl carbamic acid tert-butyl ester with the dried over sodium sulfate organic phase, be colorless oil (47.1g).
Step B
(47.1g, 0.230mol) solution in the 1L anhydrous methylene chloride is cooled to 0 ℃ also with triethylamine (48.0mL, 0.345mol) processing with 2-(2-hydroxyl-oxethyl) the ethyl carbamic acid tert-butyl ester in nitrogen atmosphere.In 30 minutes, be added dropwise to methylsulfonyl chloride (19.6mL, 0.253mol).Making reaction mixture be warming to room temperature and continue stirred 22 hours.Adding the 500mL saturated sodium bicarbonate solution makes the reaction cancellation and separates organic layer.Water (3 * 500mL) and salt water washing organic phase.Obtain methylsulfonic acid 2-{2-[(tert-butoxycarbonyl with dried over sodium sulfate and concentrated organic phase) amino] oxyethyl group } ethyl ester, be brown oil (63.5g).
Step C
Use NaN
3(16.1g 0.247mol) handles methylsulfonic acid 2-{2-[(tert-butoxycarbonyl) amino] oxyethyl group } ethyl ester (63.5g, 0.224mol) in 400mL N, the solution of dinethylformamide (DMF), and in nitrogen atmosphere, be heated to 90 ℃.The solution cool to room temperature is also used the 500mL cold water treatment after 5 hours.Use ether (3 * 300mL) abstraction reaction mixtures, and water (4 * 100mL) and the salt solution (organic layer that 2 * 100mL) washings merge then.Organic phase also concentrates with dried over mgso and obtains 52.0g 2-(2-azido-oxyethyl group) the ethyl carbamic acid tert-butyl ester, is light brown oily thing.
Step D
Handle 2-(2-azido-oxyethyl group) the ethyl carbamic acid tert-butyl ester (47.0g, methanol solution 0.204mol) and (3Kg/cm in hydrogen atmosphere with 10% palladium/charcoal of 4g
2) vibrated 24 hours.Obtain 35.3g 2-(2-amino ethoxy) ethyl carbamic acid tert-butyl ester crude product by the Celite pad filtering solution is also concentrated, be colourless liquid, it need not be further purified and can directly use.
Step e
In nitrogen atmosphere, with triethylamine (43mL, 0.308mol) and 2-(2-amino ethoxy) the ethyl carbamic acid tert-butyl ester (0.151mol) handle 4-chloro-3-nitroquinoline in the stirring (31.4g be 0.151mol) in the solution of 500mL anhydrous methylene chloride.Stirring is spent the night, water (2 * 300mL) and salt solution (300mL) washing reaction mixture.Organic phase also concentrates with dried over sodium sulfate and obtains the bright yellow solid.Obtain 2-{2-[(3-nitroquinoline-4-yl of 43.6g with the ethyl acetate/hexane recrystallization) amino] oxyethyl group } the ethyl carbamic acid tert-butyl ester, be the bright yellow crystal.
Step F
5% platinum/charcoal with 1.5g is handled 2-{2-[(3-nitroquinoline-4-yl) amino] oxyethyl group } the ethyl carbamic acid tert-butyl ester (7.52g, toluene solution 20.0mmol) and (3Kg/cm in hydrogen atmosphere
2) vibrated 24 hours.By Celite pad filtering solution and the concentrated 2-{2-[(3-quinolylamine-4-yl that obtains 6.92g) amino] oxyethyl group } ethyl carbamic acid tert-butyl ester crude product, be yellow slurry.
Step G
With 2-{2-[(3-quinolylamine-4-yl) amino] oxyethyl group } (3.46g is 10.0mmol) in solution orthovaleric acid triethyl (2.5mL, 14.5mmol) processing, the heating reflux reaction mixture then of 50mL toluene for the ethyl carbamic acid tert-butyl ester.Then add 25mg pyridine hydrochloride, continue to reflux 4 hours.The concentrating under reduced pressure reactant is to doing, and residue is dissolved in the 50mL methylene dichloride, uses saturated sodium bicarbonate, water and salt water washing.With the organic layer dried over sodium sulfate, concentrate and obtain green oil.Continuation is dissolved in green oil in the 50mL hot methanol, and uses activated carbon treatment, and filtering heat solution also concentrates 2-[2-(2-butyl-1H-imidazo [4, the 5-c] quinoline-1-yl) oxyethyl group that obtains 4.12g] the ethyl carbamic acid tert-butyl ester, be yellow oil.
Step H
With the 3-chloroperoxybenzoic acid (MCPBA, 77%, 2.5g 11.2mmol) handles 2-[2-(2-butyl-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group] (4.12g is 10.0mmol) in the solution of 50mL methylene dichloride for the ethyl carbamic acid tert-butyl ester.Stir and handle with saturated sodium bicarbonate solution after 5 hours, and separate each layer, water and salt water washing organic layer, use dried over sodium sulfate, and concentrated 2-[2-(the 2-butyl-5-oxidation-1H-imidazo [4 that obtains 3.68g, 5-c] quinoline-1-yl) oxyethyl group] the ethyl carbamic acid tert-butyl ester, be the light brown foam.
Step I
With 2-[2-(2-butyl-5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group] (3.68g, 8.60mmol) in 1 of 100mL, the solution of 2-ethylene dichloride is heated to 80 ℃ and also handles with the 10mL ammonium hydroxide solution,stronger ethyl carbamic acid tert-butyl ester.In 10 minutes, add in the solution under quick stirring Tosyl chloride (1.87g, 9.81mmol).Then reaction mixture is sealed in the pressurized vessel heating and continuous 2 hours.Reaction mixture is also handled with the 100mL methylene dichloride then.Water, 1% sodium carbonate solution (3X) and salt solution washing reaction mixture then.With dried over sodium sulfate organic layer and concentrated 2-[2-(4-amino-2-butyl-1H-imidazo [4, the 5-c] quinoline-1-yl) oxyethyl group that obtains 3.68g] the ethyl carbamic acid tert-butyl ester, be the light brown foam.
Step J
With 2-[2-(4-amino-2-butyl-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group] (3.68g 8.60mL) is suspended in the ethanolic soln of 20mL 2M HCl and reflux mixture under agitation the ethyl carbamic acid tert-butyl ester.Concentrated reaction mixture obtains solid after 3 hours.Grind with hot ethanol (50mL), and filter and obtain the 2.90g hydrochloride product, this hydrochloride is dissolved in the 50mL water and with the dense NH of 5mL
4OH handles and obtains its free alkali.Then, the usefulness methylene dichloride (3 * 50mL) extract aqeous suspensioies, merge organic layer, and use dried over sodium sulfate, obtain 1-[2-(2-amino ethoxy) ethyl]-2-butyl-1H-imidazo [4,5-c] quinoline-4-amine, be chocolate brown powder.
MS 328(M+H)
+；
1H NMR(300MHz，CDCl
3)δ7.95(d，J＝8.3Hz，1H)；7.83(d，J＝8.4Hz，1H)；7.50(m，1H)；7.30(m，1H)；5.41(s，2H)；4.69(t，J＝5.6Hz，2H)；3.93(t，J＝5.6Hz，2H)；3.39(t，J＝5.1Hz，2H)；2.97(t，J＝7.9Hz，2H)；2.76(t，J＝5.1Hz，2H)；1.89(m，2H)；1.52(m，2H)；1.26(br s，2H)；1.01(t，J＝7.3Hz，3H).
Embodiment 2
1-[2-(2-amino ethoxy) ethyl]-1H-imidazo [4,5-c] quinoline-4-amine
Steps A
With 2-{2-[(3-quinolylamine-4-yl) amino] oxyethyl group } (6.92g, 20.0mmol) (4.65mL 28.0mmol) handles, then with the reaction mixture reflux ethyl carbamic acid tert-butyl ester with triethyl orthoformate in the solution of 100mL toluene.Then add 100mg pyridine hydrochloride, continue to reflux 2 hours.The concentrating under reduced pressure reactant is to doing, and residue is dissolved in the 200mL methylene dichloride, with saturated sodium bicarbonate, water and salt water washing.With the organic layer dried over sodium sulfate, concentrate and obtain green oil.Continuation is dissolved in green oil in the 200mL hot methanol, and uses the 10g activated carbon treatment, and filtering heat solution also concentrates 2-[2-(1H-imidazo [4, the 5-c] quinoline-1-yl) oxyethyl group that obtains 5.25g] the ethyl carbamic acid tert-butyl ester, be pale yellow syrup.
Step B
With MCPBA (77%, 3.63g 16.3mmol) handles 2-[2-(1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group] (5.25g is 14.7mmol) in the solution of 200mL methylene dichloride for the ethyl carbamic acid tert-butyl ester.After spending the night, stirring uses the saturated sodium bicarbonate solution reaction mixture, and separate each layer, water and salt water washing organic layer, use dried over sodium sulfate, and concentrated 2-[2-(the 5-oxidation-1H-imidazo [4 that obtains 4.60g, 5-c] quinoline-1-yl) oxyethyl group] the ethyl carbamic acid tert-butyl ester, be the light brown foam.
Step C
With 2-[2-(5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group] (4.60g, 12.4mmol) in 1 of 150mL, the solution of 2-ethylene dichloride is heated to 80 ℃ and also handles with the 10mL ammonium hydroxide solution,stronger ethyl carbamic acid tert-butyl ester.In 10 minutes, add in the solution under quick stirring Tosyl chloride (2.71g, 14.2mmol).Be sealed in the pressurized vessel heating and continuous 3 hours more then with 2mL ammonium hydroxide solution,stronger reaction mixture.Reaction mixture is also handled with the 100mL ethylene dichloride then.Water, 1% sodium carbonate solution (3X) and salt solution washing reaction mixture then.With dried over sodium sulfate organic layer and concentrated 2-[2-(4-amino-1H-imidazo [4, the 5-c] quinoline-1-yl) oxyethyl group that obtains 4.56g] the ethyl carbamic acid tert-butyl ester, be the light brown foam.
Step D
With 2-[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group] the ethyl carbamic acid tert-butyl ester (4.56g 12.3mL) is dissolved in the 100mL ethanol, handles with the ethanolic soln of 30mL 2M HCl, and reflux mixture under agitation.After 3 hours, with the concentrated solid that obtains of reaction mixture.Solid grinds with hot ethanol (100mL), and filtration obtains hydrochloride product.This hydrochloride is dissolved in the 50mL water also with the dense NH of 5mL
4The OH solution-treated obtains its free alkali.Then, the usefulness methylene dichloride (5 * 50mL) extract aqeous suspensioies, merge organic layer, and use dried over sodium sulfate, concentrate and obtain 1.35g 1-[2-(2-amino ethoxy) ethyl]-2-butyl-1H-imidazo [4,5-c] quinoline-4-amine, be chocolate brown powder.
MS 272(M+H)
+；
1H NMR(300MHz，CDCl
3)δ7.98(d，J＝8.2Hz，1H)；7.88(s，1H)；7.84(d，J＝8.4Hz，1H)；7.54(m，1H)；7.32(m，1H)；5.43(s，2H)；4.74(t，J＝5.2Hz，2H)；3.97(t，J＝5.2Hz，2H)；3.42(t，J＝5.1Hz，2H)；2.78(t，J＝5.1Hz，2H)；1.10(br s，2H).
Embodiment 3
1-[2-(2-amino ethoxy) ethyl]-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-4-amine
Steps A
With 2-{2-[(3-quinolylamine-4-yl) amino] oxyethyl group } (10.2g 29.5mmol) is dissolved in the anhydrous methylene chloride of 250mL and is cooled to 0 ℃ the ethyl carbamic acid tert-butyl ester.Use then triethylamine (4.18mL 30.0mmol) handles resulting reaction mixture, in 5 minutes, add the methoxy propyl acyl chlorides (3.30mL, 30.3mmol).Be heated to stirring at room 1 hour, and, obtained orange solid the reaction mixture concentrating under reduced pressure.Be dissolved in then in the 250mL ethanol, and add the 12.5mL triethylamine.Then under nitrogen, reactant reflux and stirring are spent the night.Again reaction mixture is evaporated to dried, handle with the 300mL ether, filtering mixt and concentrating under reduced pressure filtrate, obtain brown solid, above-mentioned solid is dissolved in the 200mL hot methanol, and uses activated carbon treatment, filtering heat solution also concentrates 2-{2-[2-(2-the methoxy ethyl)-1H-imidazo [4 that obtains 11.1g, 5-c] quinoline-1-yl] oxyethyl group } the ethyl carbamic acid tert-butyl ester, be yellow slurry.
Step B
With MCPBA (77%, 9.12g 40.8mmol) handles 2-{2-[2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group (10.22g is 24.7mmol) in the solution of 250mL chloroform for the ethyl carbamic acid tert-butyl ester.Stir after 30 minutes with 1% sodium hydrogen carbonate solution (2 * 75mL) and the salt water washing, use the dried over sodium sulfate organic layer, and concentrated 2-{2-[2-(2-the methoxy ethyl)-5-oxidation-1H-imidazo [4 that obtains 10.6g, 5-c] quinoline-1-yl] oxyethyl group } the ethyl carbamic acid tert-butyl ester, be orange foam, do not need to be further purified and carry out next step reaction.
Step C
With 2-{2-[2-(2-methoxy ethyl)-5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } the ethyl carbamic acid tert-butyl ester (10.6g, 24.6mmol) in 1 of 100mL, the solution of 2-ethylene dichloride is heated to 60 ℃ and also handles with the 10mL ammonium hydroxide solution,stronger.In 10 minutes, and adding solid Tosyl chloride in the solution under quick stirring (7.05g, 37.0mmol).Be sealed in the pressurized vessel heating and continuous 2 hours more then with 1mL ammonium hydroxide solution,stronger reaction mixture.Reaction mixture is also handled with the 100mL chloroform then.Water, 1% sodium carbonate solution (2X) and salt solution washing reaction mixture then.With dried over sodium sulfate organic layer and concentrated 2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4, the 5-c] quinoline-1-yl that obtains 10.6g] oxyethyl group } the ethyl carbamic acid tert-butyl ester, be brown foam.
Step D
With 2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } the ethyl carbamic acid tert-butyl ester (10.6g, 24.6mmol) handle with the ethanolic soln of 75mL 2M HCl, and heating reflux reaction mixture under agitation.1.5 hour postcooling reaction mixture and filtration obtain viscous solid.Obtain hydrochloride with ethanol and ether washing gained solid and vacuum-drying, be light brown powder.This hydrochloride is dissolved in the 50mL water and obtains its free alkali with the processing of 10% sodium hydroxide solution.Condensed water suspension is extremely done, and handles residue with chloroform.Filter and remove resulting salt, concentrated filtrate obtains 1-[2-(2-amino ethoxy) ethyl of 3.82g]-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-4-amine, be brown powder.
MS 330(M+H)
+；
1H NMR(300MHz，DMSO-d
6)δ8.10(d，J＝8.1Hz，1H)；7.66(d，J＝8.2Hz，1H)；7.40(m，1H)；7.25(m，1H)；6.88(br s，2H)；4.78(t，J＝5.4Hz，2H)；3.89(t，J＝4.8Hz，2H)；3.84(t，J＝6.9Hz，2H)；3.54(t，J＝5.4Hz，2H)；3.31(s，3H)；3.23(t，J＝6.6Hz，2H)；2.88(t，J＝5.3Hz，2H).
Embodiment 4
N-(2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl) benzamide
In nitrogen atmosphere with 1-[2-(2-amino ethoxy) ethyl]-(750mg 2.28mmol) is dissolved in the anhydrous methylene chloride of 35mL and is cooled to 0 ℃ 2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-4-amine.In stirring solution down, add triethylamine (0.35mL, 2.50mmol) and Benzoyl chloride (260 μ L 2.28mmol), make reaction mixture arrive room temperature at 2.5 hours internal heating.Add saturated sodium bicarbonate solution (30mL) and methylene dichloride (30mL) and make the reaction cancellation.And separation organic layer, water and salt water washing organic phase.Obtain brown foam thing with dried over sodium sulfate and concentrating under reduced pressure organic phase.Mass spectroscopy shows that also there are some bisamides in the product except expectation.Brown foam thing was handled 5 hours down at 100 ℃ with 1N aqueous hydrochloric acid (50mL), and efficient liquid phase chromatographic analysis shows that all bisamides all change into the product of expectation.With the reaction mixture cool to room temperature, and be about 11 with 10% sodium-hydroxide treatment up to pH, (3 * 30mL) extract mixtures with chloroform, the organic extraction that water and salt water washing are extracted, and use dried over sodium sulfate, concentrating under reduced pressure obtains yellow solid, by column chromatography (SiO
2, 5-10% methyl alcohol/chloroform) and purifying obtains 100mg N-(2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl) benzamide, is white powder.Fusing point 184-187 ℃.
MS 434(M+H)
+；
1H NMR(300MHz，DMSO-d
6)δ8.40(m，1H)；8.06(d，J＝8.3Hz，1H)；7.76-7.74(m，2H)；7.60(d，J＝7.8Hz，1H)；7.54-7.37(m，4H)；7.19(t，J＝7.3Hz，1H)；6.48(s，2H)；4.79-4.72(m，2H)；3.91-3.84(m，2H)；3.78(t，J＝6.9Hz，2H)；3.48(t，J＝5.5Hz，2H)；3.25(s，3H)；3.20(t，J＝6.3Hz，2H)；
13C(75MHz，DMSO-d
6)δ166.7，152.0，151.9，145.2，134.8，132.7，131.4，128.6，127.4，126.7，121.4，120.5，115.1，70.4，69.4，69.2，58.4，45.5，27.6.
Embodiment 5
1-[2-(2-amino ethoxy) ethyl]-2-(2-methoxy ethyl)-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine
With 1-[2-(2-amino ethoxy) ethyl]-(10.0g 27.3mmol) is dissolved in the 50mL trifluoroacetic acid and uses PtO 2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-4-amine
2(1.0g) handle.(3Kg/cm in hydrogen atmosphere
2) the oscillatory reaction mixture, add PtO after 4 days again
20.5g and continued hydrogenation 3 days.By the Celite pad filter reaction mixture, concentrating under reduced pressure obtains brown oil then.The yellow oil of gained is dissolved in the 200mL water and by adding 10% sodium hydroxide solution is transferred to alkalescence (pH～11), use chloroform (5 * 75mL) extractions and the organic layer that merges with dried over sodium sulfate then, obtain 1-[2-(2-amino ethoxy) ethyl of 5.17g after concentrating]-2-(2-methoxy ethyl)-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine is brown solid.
MS 334(M+H)
+；
1H NMR(300MHz，CDCl
3)δ5.19(s，2H)；4.49(t，J＝5.4Hz，2H)；3.84(t，J＝6.6Hz，2H)；3.71(t，J＝5.4Hz，2H)，3.36(t，J＝5.2Hz，2H)；3.51(s，3H)；3.15(t，J＝6.6Hz，2H)；2.95(m，2H)；2.82(m，2H)；2.76(t，J＝5.1Hz，2H)；1.84(m，4H)，1.47(br s，2H).
Embodiment 6
N-(2-{2-[4-amino-2-(2-methoxy ethyl)-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl) benzamide
In nitrogen atmosphere with 1-[2-(2-amino ethoxy) ethyl]-2-(2-methoxy ethyl)-6,7,8, (1.00g 3.00mmol) is dissolved in the anhydrous methylene chloride of 30mL and is cooled to 0 ℃ 9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine.Add in the solution under stirring triethylamine (0.84mL, 6.00mmol) and Benzoyl chloride (348 μ L 3.00mmol), make reaction mixture be heated to ambient temperature overnight.Add saturated sodium bicarbonate solution (30mL) and make the reaction cancellation.And separation organic layer, water and salt water washing organic phase.Obtain yellow oil with dried over sodium sulfate and concentrating under reduced pressure organic phase.Oil is dissolved in a spot of hot methanol, and handle with ether (50mL), obtain white precipitate, filtering separation solid and vacuum-drying obtain 476mg N-(2-{2-[4-amino-2-(2-methoxy ethyl)-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl) benzamide, be white powder.Molten some 141-143 ℃.
MS 438(M+H)
+；
1H NMR(300MHz，DMSO-d
6)δ8.36(t，J＝5.4Hz，1H)；7.78-7.76(m，2H)；7.54-7.42(m，3H)；5.68(s，2H)；4.43(t，J＝5.4Hz，2H)；3.75-3.69(m，4H)；3.48(t，J＝6.0Hz，2H)；3.37(t，J＝5.5Hz，2H)；3.24(s，3H)；3.07(t，J＝6.9Hz，2H)；2.91(m，2H)；2.63(m，2H)；1.70(m，4H)；
13C(75MHz，DMSO-d
6)δ166.7，151.3，149.3，146.2，138.5，134.8，131.4，128.6，127.5，124.9，105.6，70.5，70.5，69.3，58.4，44.6，32.7，27.6，23.8，23.0，23.0.
Ultimate analysis: theoretical value C
24H
31N
5O
3: %C, 65.88; %H, 7.14; %N, 16.01. measured value: %C, 65.55; %H, 7.15; %N, 15.87.
Embodiment 7
2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group] ethyl }-1H-imidazo [4,5-c] quinoline-4-amine
Steps A
In nitrogen atmosphere, with sodium hydride (60% oil suspension, 9.1g, 228mmol) place round-bottomed flask, and wash with hexane (3 *), anhydrous THF with 800mL handles dry sodium hydride, and (41.9g is 182mmol) in the solution of 200mL tetrahydrofuran (THF) is added to sodium hydride solution under stirring with 2-(2-azido-oxyethyl group) the ethyl carbamic acid tert-butyl ester in 40 minutes then.Add finish after, continued stirring reaction 20 minutes, then add methyl iodide (13.6mL, 218mmol).Stirring is spent the night, and adds the 300mL saturated sodium bicarbonate solution and makes the reaction cancellation.Then, water 200mL and 1L ether reaction mixture.Separate organic phase and water and salt water washing organic phase.Obtain 2-(2-azido-oxyethyl group) ethyl (methyl) t-butyl carbamate of 41.9g with dried over mgso and concentrating under reduced pressure organic phase, be yellow liquid.
Step B
With 10% palladium of 2.5g/charcoal handle 2-(2-azido-oxyethyl group) ethyl (methyl) t-butyl carbamate (41.9g, 170mmol) in the solution of 600mL methyl alcohol and in hydrogen atmosphere (3Kg/cm
2) vibrated 24 hours.Obtain 37.2g 2-(2-amino ethoxy) ethyl (methyl) t-butyl carbamate crude product by the Celite pad filtering solution is also concentrated, be light yellow liquid.
Step C
In nitrogen atmosphere, use triethylamine (43.1mL, 310mmol) and 2-(2-amino ethoxy) ethyl (methyl) t-butyl carbamate (37.2g, (32.3g is 155mmol) in the solution of 400mL anhydrous methylene chloride for 4-chloro-3-nitroquinoline under 171mmol) processing is stirred.Stirring is spent the night, water (2 * 300mL) and salt solution (300mL) washing reaction mixture.Obtain brown oil with dried over sodium sulfate and concentrated organic phase.By column chromatography (SiO
2, 33% ethyl acetate/hexane-67% ethyl acetate/hexane) and obtain 46.7g methyl (2-{2-[(3-nitroquinoline-4-yl) amino] oxyethyl group } ethyl) t-butyl carbamate, be yellow solid.
Step D
Handle methyl (2-{2-[(3-nitroquinoline-4-yl) amino with 5% platinum of 0.5g/charcoal] oxyethyl group ethyl) t-butyl carbamate (and 6.56g, 16.8mmol) in the solution of 75mL toluene, and in hydrogen atmosphere (3Kg/cm
2) vibrated 24 hours.By Celite pad filtering solution and the concentrated 2-{2-[(3-quinolylamine-4-yl that obtains 6.8g) amino] oxyethyl group } ethyl (methyl) t-butyl carbamate crude product, be orange slurries.It need not be further purified and can use.
Step e
With 2-{2-[(3-quinolylamine-4-yl) amino] oxyethyl group } (6.05g, 16.8mmol) solution in the 200mL anhydrous methylene chloride is cooled to 0 ℃ to ethyl (methyl) t-butyl carbamate, and (2.40mL 17.2mmol) handles with triethylamine.In 5 minutes, be added dropwise to the methoxy propyl acyl chlorides (1.72mL, 17.2mmol).Making reaction mixture be warming to room temperature and continue stirred 3 hours.The concentrating under reduced pressure reaction mixture obtains orange solids.Be dissolved in it in 200mL ethanol and add the triethylamine of 7.2mL.The heating reflux reaction mixture also stirs in nitrogen atmosphere and spends the night.Then reaction mixture being concentrated to dry doubling handles with the ether of 300mL.Filter reaction mixture and concentrating under reduced pressure filtrate obtain brown solid.Be dissolved in the 300mL methylene dichloride gained solid and water and salt water washing.Use the dried over sodium sulfate organic layer, and concentrating under reduced pressure obtains brown oil.This oily matter is dissolved in the methyl alcohol of 100mL heat and uses activated carbon treatment.Filtering heat solution also concentrates 2-{2-[2-(2-methoxy ethyl)-1H-imidazo [4, the 5-c] quinoline-1-yl that obtains 7.20g] oxyethyl group } ethyl (methyl) t-butyl carbamate, be yellow slurry.
Step F
With MCPBA (77%, 4.32g 19.3mmol) handles 2-{2-[2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group (7.20g is 16.8mmol) in the solution of 200mL methylene dichloride for ethyl (methyl) t-butyl carbamate.Stir after 6 hours with saturated sodium bicarbonate solution processing reaction miscellany and separate each layer.Water and salt water washing organic phase.Obtain 2-{2-[2-(2-methoxy ethyl)-5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl of 7.05g with dried over sodium sulfate and concentrated organic phase] oxyethyl group } ethyl (methyl) t-butyl carbamate, be the light brown solid.
Step G
With 2-{2-[2-(2-methoxy ethyl)-5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl (methyl) t-butyl carbamate (7.05g, 15.9mmol) in 1 of 100mL, the solution of 2-ethylene dichloride is heated to 80 ℃ and also handles with the 5mL ammonium hydroxide solution,stronger.In 10 minutes, and adding solid Tosyl chloride in the solution under quick stirring (3.33g, 17.5mmol).Be sealed in the pressurized vessel heating and continuous 4 hours more then with 5mL ammonium hydroxide solution,stronger reaction mixture.Reaction mixture is also handled with the 100mL methylene dichloride then.Water, 1% sodium carbonate solution (3X) and salt solution washing reaction mixture then.With dried over sodium sulfate organic layer and concentrated 2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4, the 5-c] quinoline-1-yl that obtains 6.50g] oxyethyl group } ethyl (methyl) t-butyl carbamate, be brown oil.
Step H
With 2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl (methyl) t-butyl carbamate (6.50g, 14.7mmol) be dissolved in the 100mL ethanol and handle and heating reflux reaction mixture under agitation with the ethanolic soln of 20mL 2M HCl.6 hours postcooling reaction mixtures also filter and obtain viscous solid.Obtain hydrochloride with ethanol and ether washing gained solid and vacuum-drying, be light brown powder.This hydrochloride is dissolved in the 50mL water and obtains its free alkali with the dense ammonium hydroxide processing of 5mL.(5 * 50mL) extract aqeous suspension with methylene dichloride.Organic layer with dried over sodium sulfate merges concentrates 2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group that obtains 3.93g] ethyl }-1H-imidazo [4,5-c] quinoline-4-amine, be brown powder.MS 344(M+H)
+。
1H NMR(300MHz，DMSO-d
6)δ8.07(d，J＝7.7Hz，1H)；7.62(dd，J＝1.0，8.3Hz，1H)；7.42(ddd，J＝1.0，7.1，8.2Hz，1H)；7.22(ddd，J＝1.1，7.1，8.2Hz，1H)；6.49(s，2H)；4.75(t，J＝5.1Hz，2H)；3.83(t，J＝6.8Hz，4H)；3.35(t，J＝5.6Hz，2H)；3.30(s，3H)；3.21(t，J＝6.9Hz，2H)；2.45(t，J＝5.6Hz，2H)；2.12(s，3H).
Embodiment 8
N-(2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl)-N-methyl-benzamide
In nitrogen atmosphere with 2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group] ethyl-(1.00g 2.92mmol) is dissolved in the anhydrous methylene chloride of 30mL and is cooled to 0 ℃ 1H-imidazo [4,5-c] quinoline-4-amine.Add in the solution under stirring then triethylamine (0.81mL, 5.81mmol) and Benzoyl chloride (340 μ L 2.92mmol), and make it to be warming to ambient temperature overnight.Make the reaction mixture cancellation by adding saturated sodium bicarbonate solution (30mL) and methylene dichloride (30mL).And the separation organic layer, water and salt water washing organic phase are with dried over sodium sulfate and concentrating under reduced pressure.By column chromatography (SiO
2, 3% methyl alcohol/with the saturated chloroform of ammonium hydroxide aqueous solution) be further purified and obtain product, be colourless foam shape thing.Obtain 540mg N-(2-{2-[4-amino-2-(2-methoxy ethyl)-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl)-N-methyl-benzamide with propyl acetate and hexane recrystallization, be white powder.Fusing point 93.5-97.0 ℃.
MS 448(M+H)
+；
1H NMR(500MHz，DMSO-d
6，60℃)δ8.04(d，J＝7.7Hz，1H)；7.63(dd，J＝0.9，8.2Hz，1H)；7.42-7.33(m，4H)；7.23-7.19(m，3H)；6.24(s，2H)；4.74(m，2H)；3.86(m，2H)；3.82(t，J＝6.8Hz，2H)；3.51(m，2H)；3.40(m，2H)；3.29(s，3H)；3.18(t，J＝6.7Hz，2H)；2.75(br s，3H)；
13C NMR(125MHz，DMSO-d
6，60℃)δ152.0，151.9，145.3，137.1，132.8，131.3，129.4，128.5，127.0，126.9，126.8，126.6，121.4，120.4，l 15.3，70.5，69.5，68.8，58.4，45.5，27.8.
Ultimate analysis: theoretical value C
25H
29N
5O
3: %C, 67.09; %H, 6.53; %N, 15.65. measured value: %C, 67.08; %H, 6.56; %N, 15.58
Embodiment 9
2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group] ethyl }-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-4-amine
With 2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group] ethyl }-(4.22g 12.3mmol) is dissolved in the 25mL trifluoroacetic acid and uses PtO 1H-imidazo [4,5-c] quinoline-4-amine
2(0.5g) handle.(3Kg/cm in hydrogen atmosphere
2) the oscillatory reaction mixture, add PtO after 4 days again
20.5g and continued hydrogenation 3 days.By the Celite pad filter reaction mixture, concentrating under reduced pressure obtains yellow oil then.The yellow oil of gained is dissolved in the 50mL water, and uses the 50mL chloroform extraction, separate organic phase and discarded.Water is transferred to alkalescence (pH～12) by adding 10% sodium hydroxide solution, use chloroform (6 * 50mL) extractions and the organic layer that merges with dried over sodium sulfate then, obtain brown oil after concentrating, this oily matter is dissolved in the methyl alcohol of 100mL heat and uses the 1g activated carbon treatment.By the diatomite filtration hot solution and be concentrated into driedly, by ether viscous solid is concentrated for several times, obtain 2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group of 3.19g] ethyl }-6,7,8,9-tetrahydrochysene-lH-imidazo [4,5-c] quinoline-4-amine, be pale powder.
MS 348(M+H)
+；
1H NMR(300MHz，CDCl
3)δ4.84(s，2H)；4.48(t，J＝5.7Hz，2H)；3.84(t，J＝6.7Hz，2H)；3.70(t，J＝5.7Hz，2H)；3.46(t，J＝5.1Hz，2H)；3.36(s，3H)；3.14(t，J＝6.7Hz，2H)；2.96(m，2H)；2.83(m，2H)；2.65(t，J＝5.1Hz，2H)；2.36(s，3H)；1.85(m，4H).
Embodiment 10
N-(2-{2-[4-amino-2-(2-methoxy ethyl)-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl)-N-methyl-benzamide
In nitrogen atmosphere with 2-(2-methoxy ethyl)-1-{2-[2-(methylamino) oxyethyl group] ethyl-6,7,8, (750mg 2.16mmol) is dissolved in the anhydrous methylene chloride of 20mL and is cooled to 0 ℃ 9-1H-imidazo [4,5-c] quinoline-4-amine.Add in the solution under stirring triethylamine (0.60mL, 4.32mmol) and Benzoyl chloride (250 μ L 2.16mmol), are heated to ambient temperature overnight with reaction mixture.Add saturated sodium bicarbonate solution (30mL) and methylene dichloride (30mL) and make the reaction cancellation.And the separation organic layer, water (3X) and salt water washing organic phase are with dried over sodium sulfate and concentrating under reduced pressure.By column chromatography (SiO
2, 3% methyl alcohol/with the saturated chloroform of ammonium hydroxide aqueous solution) be further purified and obtain product, be colourless foam shape thing.Concentrated foam shape thing from Virahol, obtain slurries, it is placed curing, solid vacuum-drying obtains 408mg N-(2-{2-[4-amino-2-(2-methoxy ethyl)-6,7,8,9-tetrahydrochysene-1H-imidazo [4,5-c] quinoline-1-yl] oxyethyl group } ethyl)-N-methyl-benzamide, be linen powder.
m.p 83.0-87.0℃；
MS 452(M+H)
+；
1H NMR(500MHz，DMSO-d
6，60℃)δ7.37(m，3H)；7.23(m，2H)；5.46(s，2H)；4.43(m，2H)；3.76(t，J＝6.8Hz，2H)；3.68(m，2H)；3.50(m，2H)；3.42(m，2H)；3.27(s，3H)；3.05(t，J＝6.4Hz，2H)；2.92(m，2H)；2.80(s，3H)；2.65(m，2H)；1.74(m，4H)；
13C NMR (125MHz, DMSO-d
6, 60 ℃) and δ 150.5,148.5,145.8,137.9,136.4,128.7,127.8,126.3,124.5,105.1,70.1,69.8,68.0,57.7,44.0,32.1,27.1,23.2,22.4,22.4 ultimate analysis: theoretical value C
25H
33N
5O
30.30 C
3H
8O:%C, 66.24; %H, 7.60; %N, 14.91. measured value: %C, 65.86; %H, 7.81; %N, 15.10.
Embodiment 11
1-{1-[(2-piperidin-4-yl oxyethyl group) methyl] propyl group }-1H-imidazo [4,5-c] quinoline-4-amine
Steps A
Use the general method of EXAMPLE l steps A, through 4-piperidines ethanol (10g, 77.4mmol) and one contract that (17.7g, 81.3mmol) reaction obtains 13.1g 4-(2-hydroxyethyl) piperidines-1-carboxylic acid tert-butyl ester to tert-Butyl dicarbonate, is clarification oily matter.
Step B
Divide three parts with iodine (7.97g) and be added to imidazoles (3.89g, 57.1mmol) and triphenylphosphine (14.98g, 57.1mmol) methylene dichloride (350mL) solution in, after 5 minutes, add methylene dichloride (70mL) solution that steps A obtains product, at room temperature stirred reaction mixture spends the night, add more iodine (7.97g) then, and at room temperature stirred 1 hour, with saturated sodium thiosulfate (2X) and salt solution washing reaction mixture, dried over sodium sulfate is filtered and concentrating under reduced pressure obtains the oily residue.The gained residue obtains 4-(the 2-iodo ethyl) piperidines-1-carboxylic acid tert-butyl ester of 15.52g by column chromatography purification (with 20% ethyl acetate/hexane wash-out), is light yellow oil.
Step C
In nitrogen atmosphere, with 2-(1H-imidazo [4,5-c] quinoline-1-yl) fourth-1-alcohol (6.5g, 26.9mmol) divide three parts be added to sodium hydride (1.4g, 60%, anhydrous N 35.0mmol) is in the dinethylformamide suspension.Stirring reaction no longer produced up to gas in 45 minutes.In 15 minutes, be added dropwise to 4-(2-iodine ethyl) piperidines-1-carboxylic acid tert-butyl ester (10.05g, 29.6mmol).At room temperature stirred reaction mixture is 2.5 hours, is heated to 100 ℃ and stir and to spend the night then.The reaction of HPLC analysis revealed finishes about 35%.Add saturated ammonium chloride solution, stirred the gained reaction mixture 20 minutes, use ethyl acetate (2X) to extract then.Water (2X) and salt water washing ethyl acetate extract are used dried over sodium sulfate, and filtering also, concentrating under reduced pressure obtains brown oil.Gained oily matter is by column chromatography purification (order 30% ethyl acetate/hexane, 50% ethyl acetate/hexane and eluent ethyl acetate silica gel) obtain 4-{2-[2-(1H-imidazo [4, the 5-c] quinoline-1-yl) butoxy of 2.2g] ethyl } piperidines-1-carboxylic acid tert-butyl ester.
Step D
Use the general method of the step H of embodiment 1,, obtain 4-{2-[2-(5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl) butoxy the material oxidation of step C] ethyl } piperidines-1-carboxylic acid tert-butyl ester oily matter.
Step e
Solution of ammonium hydroxide (20mL) is added in methylene dichloride (20mL) solution of step D product, in 5 minutes, adds toluene sulfonyl chloride (0.99g, methylene dichloride 5.2mmol) (10mL) solution.The biphase reaction mixture that stirs gained spends the night, with chloroform and saturated sodium bicarbonate solution diluted reaction mixture.Separate each layer.The organic layer dried over sodium sulfate is filtered and concentrating under reduced pressure obtains brown glass shape thing.By column chromatography (using eluent ethyl acetate silica gel again with 50% ethyl acetate/hexane earlier) this material of purifying, obtain 4-{2-[2-(the 4-amino-1H-imidazo [4 of 1.0g, 5-c] quinoline-1-yl) butoxy] ethyl } piperidines-1-carboxylic acid tert-butyl ester, be light yellow hyaloid foam.
Step F
In nitrogen atmosphere, mix 4-{2-[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) butoxy] ethyl piperidines-1-carboxylic acid tert-butyl ester (1.00g, 2.1mmol) and 2N spirit of salt ethanolic soln (10mL is 20mmol) and stirring at room gained solution 14 hours.Solvent removed in vacuo, the brown solid that obtains is soluble in water.Adding saturated aqueous sodium carbonate is 10 up to pH.After methylene dichloride (3X) extraction, merge organic layer, use the salt water washing, dry (sodium sulfate) filters and vacuum is removed most solvents.Add hexane and obtain precipitation.Vacuum filtration obtains the 1-{1-[(2-piperidin-4-yl oxyethyl group of 0.5g) methyl] propyl group }-1H-imidazo [4,5-c] quinoline-4-amine, be brown powder.
1H-NMR(300MHz，DMSO-d
6)：δ8.34(bs，1H)，8.19(d，J＝8.49Hz，1H)，7.61(dd，J＝8.31，1.13Hz，1H)，7.45-7.39(m，1H)，7.25-7.19(m，1H)，6.55(s，2H)，5.25-5.15(m，1H)，4.00-3.80(m，2H)，3.5-3.3(m，2H)，2.8-2.64(m，2H)，2.22-2.11(m，2H)，2.09-1.99(m，2H)，1.8-1.63(bs，1H)，1.37-1.0(m，5H)，0.95-0.7(m，5H)；
13C-NMR(75MHz，DMSO-d
6)：δ152.8，145.8，140.6，133.0，127.8，127.0，126.9，121.3，121.0，115.5，71.8，68.1，58.4，46.1，36.3，33.1，32.7，24.5，9.9；
(368.2450 is C to MS (CI) m/e 368.2459
21H
30N
5The O theoretical value).
Embodiment 12
5-[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group]-N-methyl-N-phenyl valeramide
Use the general method of embodiment 11 step C and D, with 2-(1H-imidazo [4,5-c] quinoline-1-yl) ethanol (0.63g, 2.9mmol) and 5-bromo-N-methyl-N-phenyl valeramide (1.3g, 4.8mmol) mix, obtain 0.24g 5-[2-(5-oxidation-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group]-the clarification oily matter of N-methyl-N-phenyl valeramide.Gained N-oxide products is dissolved in the methylene dichloride, and dropwise adds trichloroacetyl isocyanate (0.11ml), reaction mixture was at room temperature stirred 2 hours, then solvent removed in vacuo.The oil that obtains is dissolved in the methyl alcohol, and slowly adds sodium methylate (0.2mL, 25 weight % are in methyl alcohol), reaction mixture is placed spent the night, then vacuum concentration.With dodging formula column chromatography (silica gel, 9: 1 ethyl acetate methyl alcohol) purifying, obtain 24mg 5-[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group]-N-methyl-N-phenyl valeramide, be white solid.
1H NMR (300MHz, CDCl
3) δ 7.94 (d, J=8.1Hz, 1H), 7.83 (m, 2H), 7.52 (dt, J=7.7,1.3Hz, 1H), 7.41-7.28 (m, 4H), 7.12 (d, J=7.8Hz, 2H), 5.55 (wide s, 2H), 4.65 (t, J=5.3Hz, 2H), 3.85 (t, J=5.3Hz, 2H), 3.31 (t, J=6.3Hz, 2H), 3.24 (s, 3H), 2.02 (m, 2H), 1.56 (m, 2H), 1.40 (m, 2H);
IR(KBr)3429，3104，2946，2877，1646，1595，1584，1532，1496，1482，1398，1360，1254，1121，749，705cm
-1；
(417.2165 is C to MS (EI) m/e 417.2160
24H
27N
5O
2Theoretical value)
Embodiment 13
5-[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group]-N-butyl-N-phenyl valeramide
Use the general method of embodiment 12, with 2-(1H-imidazo [4,5-c] quinoline-1-yl) ethanol and 5-bromo-N-butyl-N-phenyl valeramide mixing, with dodging formula column chromatography (silica gel, 98: 2 ethyl acetate methyl alcohol) purifying, obtain 5-[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) oxyethyl group]-N-butyl-N-phenyl valeramide, be colorless oil.
1H NMR (300MHz, CDCl
3) δ 7.93 (d, J=8.0Hz, 1H), 7.87-7.85 (m, 2H), 7.54 (dt, J=7.7,1.1Hz, 1H), 7.41-7.29 (m, 4H), 7.10 (d, J=7.2Hz, 2H), 6.20 (wide s, 2H), 4.66 (t, J=5.2Hz, 2H), 3.85 (t, J=5.2Hz, 2H), 3.66 (t, J=7.5Hz, 2H), 3.31 (t, J=6.2Hz, 2H), 1.96 (t, J=7.2Hz, 2H), 1.56-1.25 (m, 8H), 0.88 (t, J=7.2Hz, 3H); (459.2634 is C to MS (EI) m/e 459.2631
27H
33N
5O
2Theoretical value).
Embodiment 14
[2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) butoxy] methyl acetate
With 2-(4-amino-1H-imidazo [4,5-c] quinoline-1-yl) fourth-1-alcohol (25mg 0.0975mmol) places 2 dram (7.4mL) bottle, and add sodium hydride (5mg, 60% is suspended in mineral oil, 0.117mmol) and N, dinethylformamide (1mL).Bottle was at room temperature placed 15 minutes in ultrasonic vibrator, made the formation alkoxide.(11 μ L 0.117mmol), with reaction mixture ultrasonic vibration at room temperature 1.5 hours, confirm the formation of desired product again with the LC/MS analyze reaction mixture to add the monobromo-acetic acid methyl esters again.With method A with preparation property HPLC purification reaction mixture partly, mass measurement (Da): Theoretical Mass=328.1535, quality measurement=328.1534.
Embodiment 15-34
Adopt following general method,, can prepare the listed compound of following table according to the synthetic method of front reaction process II step (7).
Acyl chlorides (84 μ mol) is added to contains 1-[2-(2-amino ethoxy) ethyl]-test tube of methylene dichloride (5mL) solution of 2-butyl-1H-imidazo [4,5-c] quinoline-4-amine (25mg, 77 μ mol) in.Jump a queue to test tube, at room temperature in vibrator, placed 20 hours then.Remove by traditional vacuum and to desolvate.Adopt above-mentioned method B by partly preparing HPLC purifying residue.The structure of free alkali and the accurate mass (M+H) that is observed have been listed in the following table.
Embodiment 35-51
Adopt following general method,, can prepare the listed compound of following table according to the synthetic method of front reaction process II step (7).
Acyl chlorides (1.1 equivalent) is added to contains 1-{1-[(2-piperidin-4-yl oxyethyl group) methyl] propyl group-test tube of methylene dichloride (5mL) solution of 1H-imidazo [4,5-c] quinoline-4-amine (25mg) in.Jump a queue to test tube, at room temperature in vibrator, placed 20 hours then.Remove by traditional vacuum and to desolvate.Adopt above-mentioned method B by partly preparing HPLC purifying residue.The structure of free alkali and the accurate mass (M+H) that is observed have been listed in the following table.
Embodiment 52-66
Adopt following general method, according to the synthetic method of front reaction process II step (7), department is with the listed compound of preparation following table.
In test tube, mix 1-[1-(2-amino ethoxy) ethyl]-1H-imidazo [4,5-c] quinoline-4-amine (20mg) and 1-Methyl-2-Pyrrolidone (5mL), and the heating under supersound process, obtain solution.Acyl chlorides (1.1 equivalent) is added.Jump a queue to test tube, at room temperature in vibrator, placed 20 hours then.Remove by traditional vacuum and to desolvate.Adopt above-mentioned method B by partly preparing HPLC purifying residue.The structure of free alkali and the accurate mass (M+H) that is observed have been listed in the following table.
Cytokine induction effect in people's cell
Adopt vitro human hemocyte system to assess the cytokine induction effect.As Testerman etc. at " Cytokine Induction by the Immunomodulators Imiquimod and S-27609 ", Journal of Leukocyte Biology, 58, described in the 365-372 (September nineteen ninety-five), activity is that the Interferon, rabbit (α) and the tumour necrosis factor (α) (being respectively IFN and TNF) that are based upon being secreted in the substratum carry out on the based measurement.
Cultivate the blood cell culture of usefulness
The whole blood collection that will obtain from healthy people donor by venipuncture adopts Histopaque -1077 to separate blood monocyte (PBMC) on every side by density gradient centrifugation from whole blood in the EDTAvacutainer pipe.With HankShi balanced salt solution washing PBMC twice, then with 3-4 * 10
6Cell/mL is suspended in the RPMI perfect medium.PBMC suspension is added to placed in the flat sterile tissue culture plate in 48 holes of RPMI perfect medium that equal-volume contains test compound (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ).
The compound thing
Compound dissolution is arrived in the dimethyl sulfoxide (DMSO) (DMSO).The concentration of DMSO must not surpass 1% ultimate density when application of sample in culture hole.
Cultivate
The solution of test compound is added in the hole 1 that contains the RPMI perfect medium, then the diluent of preparation serial dilution in each hole.Subsequently, in each hole, add isopyknic PBMC suspension, make the concentration of test compound in required scope.The concentration of final PBMC suspension is in 1.5-2 * 10
6Cell/mL.Cover culture plate with the aseptic plastic lid, mixing was cultivated 18-24 hour in 5% carbon dioxide atmosphere at 37 ℃ then gently.
Separate
After the cultivation, 4 ℃ with 1000rpm (～200 * g) centrifugal cultivation 5-10 minutes, remove the nutrient solution supernatant liquor of acellular existence and transfer in the aseptic polypropylene tube with aseptic polypropylene valinche.Sample remains on-30 ℃ to-70 ℃ before analysis.By ELISA sample is carried out Interferon, rabbit (α) and tumour necrosis factor (α) analysis.
By ELISA sample is carried out Interferon, rabbit (α) and tumour necrosis factor (α) analysis
(PBL Biomedical Laboratories, New Brunswick NJ) measure Interferon, rabbit (α) concentration by ELISA to adopt Human Multi-Species test kit.Measurement result is represented with pg/mL.
Adopt ELISA test kit (Genzyme, Cambridge, MA; R﹠amp; D Systems, Minneapolis, MN; Or Pharmingen, San Diego CA) measures (TNF) concentration of tumour necrosis factor (α).Measurement result is represented with pg/mL.
But following table has been listed the minimum concentration of each compound inducing interferon and tumour necrosis factor.A " * " is illustrated in and does not all observe the inducing action generation under any test compound concentration; Usually the highest experimental concentration is 10 or 30 μ M.
| Cytokine induction effect in people's cell | ||
| Embodiment number | Minimal effective concentration (μ M) | |
| Interferon, rabbit | Tumour necrosis factor | |
| 12 | 3.33 | * |
| 13 | 10 | * |
| 14 | 0.37 | * |
| 15 | 0.1 | 1 |
| 16 | 0.1 | 1 |
| 17 | 1 | 1 |
| 18 | 1 | 10 |
| 19 | 1 | 10 |
| 20 | 0.1 | 10 |
| 21 | 1 | 10 |
| 22 | 0.1 | 10 |
| 23 | 1 | 10 |
| 24 | 1 | 10 |
| 25 | 1 | 10 |
| 26 | 1 | 10 |
| 27 | 1 | 10 |
| 28 | 1 | 10 |
| 29 | 1 | 10 |
| 30 | 1 | 10 |
| 31 | * | 10 |
| 32 | * | 10 |
| 33 | * | 10 |
| 34 | * | 10 |
| 35 | 0.1 | 1 |
| 36 | 1 | 1 |
| 37 | 1 | 1 |
| 38 | 1 | 10 |
| 39 | 1 | 10 |
| 40 | 1 | 1 |
| 41 | 0.1 | 1 |
| 42 | 1 | 1 |
| 43 | 1 | 10 |
| 44 | 1 | 1 |
| 45 | 0.1 | 1 |
| 46 | 0.1 | 1 |
| 47 | 1 | * |
| 48 | 0.1 | 10 |
| 49 | 1 | 10 |
| 50 | 1 | 1 |
| 51 | 10 | 10 |
| 52 | 10 | 10 |
| Cytokine induction effect in people's cell | ||
| Embodiment number | Minimal effective concentration (μ M) | |
| Interferon, rabbit | Tumour necrosis factor | |
| 53 | 10 | 10 |
| 54 | 10 | 10 |
| 55 | 1 | 10 |
| 56 | 1 | 10 |
| 57 | 10 | * |
| 58 | 10 | 10 |
| 59 | 10 | 10 |
| 60 | 10 | 10 |
| 61 | 10 | 10 |
| 62 | 1 | 10 |
| 63 | * | 10 |
| 64 | 10 | * |
| 65 | * | * |
| 66 | * | * |
Claims (23)
1. formula (I) compound or pharmaceutically acceptable salt thereof:
Wherein:
X represents-CHR
5-C
1-10Alkyl;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-C
1-10Alkyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-NR
7-CR
3-R
6-C
1-10Alkyl and-R
4-NR
7-CR
3-R
6-C
3-10Cycloalkyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
Wherein aryl is a phenyl or naphthyl, and heteroaryl is pyridyl or thienyl;
Z is-NR
5-or-O-;
R
2Expression is selected from following group:
-hydrogen;
-C
1-4Alkyl;
-C
1-2Alkyl-Y-C
1-2Alkyl;
Each R
3Expression=O;
R
4Expression C
1-4Alkyl;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6The expression key, C
1-10Alkyl, perhaps-CH
2-O-CH
2
R
7Expression H; Perhaps R
4And R
7Connect together the formation piperidine ring;
Y represents-O;
N be 0 and
R is independently selected from C
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
2. according to the compound or the salt of claim 1, wherein heteroaryl is selected from the 2-pyridyl, 3-pyridyl, 4-pyridyl and 2-thiazolyl.
3. according to the compound or the salt of claim 1, wherein X represents-CH
2-CH
2-.
4. according to the compound or the salt of claim 1, wherein X represents-CH (C
2H
5)-CH
2-.
5. according to the compound or the salt of claim 1, R wherein
2Be H.
6. according to the compound or the salt of claim 1, R wherein
2Be C
1-4Alkyl.
7. according to the compound or the salt of claim 1, R wherein
2Be-C
1-2Alkyl-O-C
1-2Alkyl.
8. formula (II) compound or pharmaceutically acceptable salt thereof:
Wherein:
X represents-CH
2-CH
2
R
1Expression is selected from following group:
-R
4-NR
7-CR
3-R
6-C
1-10Alkyl and-R
4-NR
7-CR
3-R
6-C
3-10Cycloalkyl; With
-R
4-NR
7-CR
3-R
6-phenyl;
R
2Expression is selected from following group:
-hydrogen;
-C
1-4Alkyl;
-C
1-2Alkyl-Y-C
1-2Alkyl;
Each R
3Expression=O;
R
4Expression-CH
2-CH
2
R
6The expression key;
R
7Expression H;
Y represents-O-;
N be 0 and
R is independently selected from C
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
9. compound according to Claim 8 or salt, wherein R
2Be H or C
1-4Alkyl.
10. compound according to Claim 8 or salt, wherein R
2Be-C
1-2Alkyl-O-C
1-2Alkyl.
11. contain claim 1 compound for the treatment of significant quantity or the pharmaceutical composition of salt and pharmaceutically acceptable carrier.
12. the compound of claim 1 or salt are used for application in the biosynthetic medicine of induced animal cytokine in preparation.
13. according to the application of claim 12, wherein cytokine is IFN-α.
14. the compound of claim 1 or salt are used for the treatment of application in the medicine of zoonosis toxicity disease in preparation.
15. the compound of claim 1 or salt are used for the treatment of application in the medicine of animal tumor disease in preparation.
16. compound or pharmaceutically acceptable salt thereof shown in the formula (III):
Wherein:
X represents-CHR
5-C
1-10Alkyl-;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-C
1-10Alkyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-NR
7-CR
3-R
6-C
1-10Alkyl and-R
4-NR
7-CR
3-R
6-C
3-10Cycloalkyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
Wherein aryl is a phenyl or naphthyl, and heteroaryl is pyridyl or thienyl;
Z is-NR
5-, or-O-;
R
2Expression is selected from following group:
-hydrogen;
-C
1-4Alkyl;
-C
1-2Alkyl-Y-C
1-2Alkyl;
Each R
3Expression=O;
R
4Expression C
1-4Alkyl;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6The expression key, C
1-10Alkyl or-CH
2-O-CH
2
R
7Expression H; Perhaps R
4And R
7Connect together the formation piperidine ring;
Y represents-O-;
N be 0 and
R is independently selected from C
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
17. formula (IV) compound or pharmaceutically acceptable salt thereof:
Wherein:
X represents-CHR
5-C
1-10Alkyl;
R
1Expression is selected from following group:
-R
4-CR
3-Z-R
6-C
1-10Alkyl;
-R
4-CR
3-Z-R
6-aryl;
-R
4-NR
5-CR
3-R
6-C
1-10Alkyl and-R
4-NR
5-CR
3-R
6-C3
-10Cycloalkyl;
-R
4-NR
7-CR
3-R
6-aryl;
-R
4-NR
7-CR
3-R
6-heteroaryl;
Wherein aryl is a phenyl or naphthyl, and heteroaryl is pyridyl or thienyl;
Each Z represents-NR independently of one another
5-, or-O-;
Each R
3Expression=O;
R
4Expression C
1-4Alkyl;
Each R
5Represent H or C independently of one another
1-10Alkyl;
R
6The expression key, C
1-10Alkyl, perhaps-CH
2-O-CH
2
R
7Expression H; Perhaps R
4And R
7Connect together the formation piperidine ring;
N be 0 and
R is independently selected from C
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
18. contain claim 8 compound for the treatment of significant quantity or the pharmaceutical composition of salt and pharmaceutically acceptable carrier.
19. the compound of claim 8 or salt are used for application in the biosynthetic medicine of induced animal cytokine in preparation.
20. according to the application of claim 19, wherein cytokine is IFN-α.
21. claim 8 compound or salt are used for the treatment of application in the medicine of zoonosis toxicity disease in preparation.
22. claim 8 compound or salt are used for the treatment of application in the medicine of animal tumor disease in preparation.
23. formula V compound or pharmaceutically acceptable salt thereof:
Wherein:
X represents-CHR
5-C
1-10Alkyl;
R
2Expression is selected from following group:
-hydrogen;
-C
1-4Alkyl;
-C
1-2Alkyl-Y-C
1-2Alkyl;
R
4Expression C
1-4Alkyl;
R
7Expression H, perhaps R
4And R
7Connect together the formation piperidine ring;
Y represents-O-;
N be 0 and
R is independently selected from C
1-10Alkyl, C
1-10Alkoxyl group, hydroxyl, halogen and trifluoromethyl.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25421800P | 2000-12-08 | 2000-12-08 | |
| US60/254,218 | 2000-12-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1487939A CN1487939A (en) | 2004-04-07 |
| CN1297554C true CN1297554C (en) | 2007-01-31 |
Family
ID=22963391
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA018201725A Pending CN1894244A (en) | 2000-12-08 | 2001-12-06 | Aryl ether substituted imidazoquinolines |
| CNB01820161XA Expired - Fee Related CN1253452C (en) | 2000-12-08 | 2001-12-06 | Thioether subsituted imidazoquinoline compound |
| CNB018201679A Expired - Fee Related CN1297554C (en) | 2000-12-08 | 2001-12-06 | Amido ether substituted imidazoquinolines |
| CNA018201687A Pending CN1479739A (en) | 2000-12-08 | 2001-12-06 | Heterocyclic ether substituted imidazoquinoline compounds |
| CNB018201598A Expired - Fee Related CN1247575C (en) | 2000-12-08 | 2001-12-06 | Sulfonamido ether substituted imidazoquinolines |
| CNB018199070A Expired - Fee Related CN1252070C (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinolines |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA018201725A Pending CN1894244A (en) | 2000-12-08 | 2001-12-06 | Aryl ether substituted imidazoquinolines |
| CNB01820161XA Expired - Fee Related CN1253452C (en) | 2000-12-08 | 2001-12-06 | Thioether subsituted imidazoquinoline compound |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA018201687A Pending CN1479739A (en) | 2000-12-08 | 2001-12-06 | Heterocyclic ether substituted imidazoquinoline compounds |
| CNB018201598A Expired - Fee Related CN1247575C (en) | 2000-12-08 | 2001-12-06 | Sulfonamido ether substituted imidazoquinolines |
| CNB018199070A Expired - Fee Related CN1252070C (en) | 2000-12-08 | 2001-12-06 | Urea substituted imidazoquinolines |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US6683088B2 (en) |
| EP (6) | EP1341791B1 (en) |
| JP (7) | JP2004515501A (en) |
| KR (6) | KR20030070050A (en) |
| CN (6) | CN1894244A (en) |
| AR (6) | AR035668A1 (en) |
| AT (3) | ATE296301T1 (en) |
| AU (12) | AU2002239517B2 (en) |
| BR (6) | BR0116470A (en) |
| CA (6) | CA2430844A1 (en) |
| CY (2) | CY1105586T1 (en) |
| CZ (6) | CZ20031563A3 (en) |
| DE (3) | DE60117859T2 (en) |
| DK (3) | DK1343784T3 (en) |
| EE (6) | EE200300272A (en) |
| ES (3) | ES2281456T3 (en) |
| HR (6) | HRP20030464A2 (en) |
| HU (6) | HUP0600600A2 (en) |
| IL (6) | IL155904A0 (en) |
| MX (6) | MXPA03004972A (en) |
| NO (6) | NO20032452L (en) |
| NZ (6) | NZ526086A (en) |
| PL (7) | PL365995A1 (en) |
| PT (2) | PT1341790E (en) |
| RU (6) | RU2315049C2 (en) |
| SI (1) | SI1341790T1 (en) |
| SK (6) | SK287264B6 (en) |
| TW (3) | TWI293300B (en) |
| UA (2) | UA74852C2 (en) |
| WO (6) | WO2002046192A2 (en) |
| ZA (6) | ZA200305270B (en) |
Families Citing this family (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| UA67760C2 (en) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
| JP3436512B2 (en) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | Accelerator device |
| US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6667312B2 (en) * | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
| NZ532769A (en) * | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
| CA2365732A1 (en) | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
| US6677349B1 (en) * | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| IL147953A (en) * | 2002-02-01 | 2008-04-13 | Meir Bialer | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl- |
| EP1478327B1 (en) * | 2002-02-22 | 2015-04-29 | Meda AB | Method of reducing and treating uvb-induced immunosuppression |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| CA2488801A1 (en) | 2002-06-07 | 2003-12-18 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| WO2004005472A2 (en) * | 2002-07-02 | 2004-01-15 | Southern Research Institute | Inhibitors of ftsz and uses thereof |
| ES2355819T3 (en) | 2002-08-15 | 2011-03-31 | 3M Innovative Properties Company | IMMUNOSTIMULATING COMPOSITIONS AND METHODS TO STIMULATE AN IMMUNE ANSWER. |
| AU2003299082A1 (en) | 2002-09-26 | 2004-04-19 | 3M Innovative Properties Company | 1h-imidazo dimers |
| NZ540826A (en) * | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
| WO2004060319A2 (en) | 2002-12-30 | 2004-07-22 | 3M Innovative Properties Company | Immunostimulatory combinations |
| EP1592302A4 (en) * | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
| US7485432B2 (en) * | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
| JP2006519866A (en) * | 2003-03-04 | 2006-08-31 | スリーエム イノベイティブ プロパティズ カンパニー | Prophylactic treatment of UV-induced epidermal neoplasia |
| US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
| MXPA05009488A (en) * | 2003-03-07 | 2005-12-14 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines. |
| US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| ATE556711T1 (en) * | 2003-03-13 | 2012-05-15 | 3M Innovative Properties Co | METHOD FOR IMPROVING SKIN QUALITY |
| CA2518445A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| AU2004244962A1 (en) | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
| US20040214851A1 (en) * | 2003-04-28 | 2004-10-28 | 3M Innovative Properties Company | Compositions and methods for induction of opioid receptors |
| WO2004110992A2 (en) * | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | Process for imidazo[4,5-c] pyridin-4-amines |
| US6943255B2 (en) * | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| JP2007501251A (en) * | 2003-08-05 | 2007-01-25 | スリーエム イノベイティブ プロパティズ カンパニー | Infection prevention using immune response modifier compounds |
| AU2004266641A1 (en) * | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Oxime substituted imidazo-containing compounds |
| US7799800B2 (en) * | 2003-08-14 | 2010-09-21 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| JP4913593B2 (en) * | 2003-08-14 | 2012-04-11 | スリーエム イノベイティブ プロパティズ カンパニー | Lipid-modified immune response modifier |
| CA2551075A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
| AU2004268616B2 (en) | 2003-08-25 | 2010-10-07 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| NZ545412A (en) * | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| WO2005020995A1 (en) * | 2003-09-02 | 2005-03-10 | 3M Innovative Properties Company | Methods related to the treatment of mucosal associated conditions |
| US20050054665A1 (en) * | 2003-09-05 | 2005-03-10 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| US20050059072A1 (en) * | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
| US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| WO2005032484A2 (en) * | 2003-10-03 | 2005-04-14 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| MY146124A (en) | 2003-10-03 | 2012-06-29 | 3M Innovative Properties Co | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| WO2005041891A2 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
| JP2007511535A (en) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | Hydroxylamine substituted imidazo ring compounds |
| JP2007511527A (en) * | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | Oxime-substituted imidazo ring compounds |
| WO2005054237A1 (en) * | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| AR046845A1 (en) * | 2003-11-21 | 2005-12-28 | Novartis Ag | DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES |
| CA2547085A1 (en) * | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| NZ547467A (en) * | 2003-11-25 | 2010-06-25 | 3M Innovative Properties Co | Substituted imidazo ring system and methods |
| WO2005055932A2 (en) * | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
| AU2004315771A1 (en) * | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
| JP2007530450A (en) * | 2003-12-29 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | Piperazine, [1,4] diazepan, [1,4] diazocan, and [1,5] diazocan condensed imidazo ring compounds |
| WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
| JP2007517044A (en) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide |
| US20050158325A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
| US20070167479A1 (en) * | 2004-03-15 | 2007-07-19 | Busch Terri F | Immune response modifier formulations and methods |
| CA2559863A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| US20070166384A1 (en) * | 2004-04-09 | 2007-07-19 | Zarraga Isidro Angelo E | Methods , composition and preparations for delivery of immune response modifiers |
| US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| AU2005283085B2 (en) * | 2004-06-18 | 2012-06-21 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006026760A2 (en) * | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
| PL1789042T3 (en) * | 2004-09-02 | 2012-09-28 | 3M Innovative Properties Co | 1-alkoxy 1h-imidazo ring systems and methods |
| JP2008511683A (en) | 2004-09-02 | 2008-04-17 | スリーエム イノベイティブ プロパティズ カンパニー | 2-Amino 1H-imidazo ring structure and method |
| WO2006029223A2 (en) * | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
| MX2007003078A (en) * | 2004-09-14 | 2007-05-16 | Novartis Vaccines & Diagnostic | Imidazoquinoline compounds. |
| JP2008515928A (en) * | 2004-10-08 | 2008-05-15 | スリーエム イノベイティブ プロパティズ カンパニー | Adjuvants for DNA vaccines |
| US20110070575A1 (en) * | 2004-12-08 | 2011-03-24 | Coley Pharmaceutical Group, Inc. | Immunomodulatory Compositions, Combinations and Methods |
| US8080560B2 (en) * | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| US8461174B2 (en) | 2004-12-30 | 2013-06-11 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| JP5313502B2 (en) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds |
| AU2005323023A1 (en) * | 2004-12-30 | 2006-07-13 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
| US7943609B2 (en) | 2004-12-30 | 2011-05-17 | 3M Innovative Proprerties Company | Chiral fused [1,2]imidazo[4,5-C] ring compounds |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| JP5122980B2 (en) * | 2005-02-09 | 2013-01-16 | スリーエム イノベイティブ プロパティズ カンパニー | Alkyloxy-substituted thiazoloquinolines and alkyloxy-substituted thiazolonaphthylidenes |
| JP2008530252A (en) | 2005-02-09 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Thiazolo [4,5-c] ring compounds and methods substituted with oximes and hydroxylamines |
| AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| WO2006091394A2 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
| SG164344A1 (en) | 2005-02-18 | 2010-09-29 | Novartis Vaccines & Diagnostics Srl | Immunogens from uropathogenic escherichia coli |
| DK2351772T3 (en) | 2005-02-18 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli |
| US8158794B2 (en) * | 2005-02-23 | 2012-04-17 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| AU2006216799A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
| WO2006098852A2 (en) * | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
| AU2006216686A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
| CN101175493A (en) | 2005-03-14 | 2008-05-07 | 3M创新有限公司 | Methods of treating actinic keratoses |
| CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| CA2602683A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
| AU2006241166A1 (en) * | 2005-04-25 | 2006-11-02 | 3M Innovative Properties Company | Immunostimulatory compositions |
| WO2007011777A2 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
| EP1922317A4 (en) | 2005-09-09 | 2009-04-15 | Coley Pharm Group Inc | Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods |
| ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
| AU2006310337B9 (en) | 2005-11-04 | 2013-11-28 | Novartis Ag | Adjuvanted influenza vaccines including cytokine-inducing agents |
| US8088790B2 (en) * | 2005-11-04 | 2012-01-03 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
| US8697087B2 (en) | 2005-11-04 | 2014-04-15 | Novartis Ag | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| PL1945252T3 (en) | 2005-11-04 | 2013-11-29 | Seqirus Uk Ltd | Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene |
| WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| US20100010217A1 (en) * | 2006-03-23 | 2010-01-14 | Valiante Nicholas M | Methods for the preparation of imidazole-containing compounds |
| US8173657B2 (en) * | 2006-03-23 | 2012-05-08 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| US8063063B2 (en) * | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| CN101448523A (en) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | Storage of influenza vaccines without refrigeration |
| SG173336A1 (en) | 2006-03-31 | 2011-08-29 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| US20100015168A1 (en) | 2006-06-09 | 2010-01-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| US20100166788A1 (en) | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
| WO2008030511A2 (en) * | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
| JP5954921B2 (en) | 2006-09-11 | 2016-07-20 | ノバルティス アーゲー | Production of influenza virus vaccine without eggs |
| WO2008068631A2 (en) | 2006-12-06 | 2008-06-12 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| EA201070066A1 (en) | 2007-06-27 | 2010-06-30 | Новартис Аг | VACCINES AGAINST FLU WITH LOW CONTENT OF ADDITIVES |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| GEP20125605B (en) * | 2008-01-15 | 2012-08-10 | Meda Ab | Application of imidazoquinoline derivatives for colon diseases treatment or prevention of colorectal carcinoma |
| HRP20150892T1 (en) | 2008-03-03 | 2015-09-25 | Novartis Ag | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR ACTIVITY |
| AU2009227674C1 (en) | 2008-03-18 | 2015-01-29 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
| ES2733084T3 (en) | 2009-03-06 | 2019-11-27 | Glaxosmithkline Biologicals Sa | Chlamydia antigens |
| CA2756412C (en) | 2009-03-25 | 2019-02-26 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
| SG175092A1 (en) | 2009-04-14 | 2011-11-28 | Novartis Ag | Compositions for immunising against staphylococcus aerus |
| WO2010125461A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Adjuvanted vaccines for protecting against influenza |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| AU2013203591B2 (en) * | 2009-05-01 | 2017-01-19 | University Court Of The University Of Dundee | Treatment or prophylaxis of proliferative conditions |
| ES2918381T3 (en) | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for producing the same |
| WO2011007257A1 (en) | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| PT2606047T (en) | 2010-08-17 | 2017-04-07 | 3M Innovative Properties Co | Lipidated immune response modifier compound compositions, formulations, and methods |
| ES2575688T3 (en) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy |
| LT2667892T (en) | 2011-01-26 | 2019-05-10 | Glaxosmithkline Biologicals Sa | Rsv immunization regimen |
| AU2012255971A1 (en) | 2011-05-13 | 2013-05-02 | Novartis Ag | Pre-fusion RSV F antigens |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| CN103582640B (en) | 2011-06-03 | 2015-11-25 | 3M创新有限公司 | Diazanyl 1H-imidazoquinoline-4-amine and the conjugate be made up of it |
| WO2012167088A1 (en) | 2011-06-03 | 2012-12-06 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
| MX354924B (en) | 2011-11-07 | 2018-03-22 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen. |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| CN103566377A (en) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | Targeted immunotherapy for cancer |
| SMT202000597T1 (en) | 2013-01-07 | 2021-01-05 | Univ Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
| WO2015011254A1 (en) | 2013-07-26 | 2015-01-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
| PE20160849A1 (en) | 2013-11-05 | 2016-09-14 | 3M Innovative Properties Co | INJECTION FORMULATIONS BASED ON SESAME OIL |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| CA2936376A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Conjugated compounds and compositions for targeted immunotherapy |
| HUE047808T2 (en) | 2014-03-26 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Mutant staphylococcal antigens |
| CN105440135A (en) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | Anti-PD-L1 conjugates for the treatment of tumors |
| CN105233291A (en) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | Combination Therapy Compositions and Methods of Combination Therapy for the Treatment of Cancer |
| JP6760919B2 (en) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Anti-PD-L1 combination for treating tumors |
| CN105461767B (en) * | 2014-08-07 | 2019-03-12 | 富力 | A kind of chemical synthesis process of forsythin |
| US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| KR102161364B1 (en) * | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors |
| JP2018531318A (en) * | 2015-09-29 | 2018-10-25 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | Polymer conjugate vaccine |
| US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
| CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | Anti-EGFR Combinations for the Treatment of Tumors |
| CN106943596A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | Anti-CD20 Combinations for Treating Tumors |
| CN106943598A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | Anti-HER2 Combinations for the Treatment of Tumors |
| KR102515202B1 (en) | 2016-11-09 | 2023-03-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Methods and compositions for modulating acquired immunity |
| CN118515666A (en) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-Amino-quinoline derivatives |
| KR20200019226A (en) | 2017-06-23 | 2020-02-21 | 버디 바이오파마슈티칼즈, 인크. | Pharmaceutical composition |
| CA3086439A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
| CA3091027A1 (en) | 2018-02-02 | 2019-08-08 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| JP7251893B2 (en) * | 2018-02-28 | 2023-04-04 | スリーエム イノベイティブ プロパティズ カンパニー | Substituted imidazo[4,5-c]quinoline compounds with N-1 branching group |
| KR20200128116A (en) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | IL-15 variants and uses thereof |
| JP7057843B2 (en) | 2018-05-23 | 2022-04-20 | ファイザー・インク | GUCY2c-specific antibodies and their use |
| BR112020022897A2 (en) | 2018-05-23 | 2021-02-23 | Pfizer Inc. | specific antibodies to cd3 and their uses |
| US11884662B2 (en) | 2018-05-24 | 2024-01-30 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| AU2019311102A1 (en) * | 2018-07-24 | 2021-02-25 | Torque Therapeutics, Inc | TLR7/8 agonists and liposome compositions |
| EP3887369B1 (en) | 2018-11-26 | 2024-05-08 | Solventum Intellectual Properties Company | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| US10906923B1 (en) * | 2019-02-07 | 2021-02-02 | Canwell Biotech Limited | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof |
| CN119455004A (en) | 2019-02-12 | 2025-02-18 | Ambrx公司 | Compositions, methods and uses comprising antibody-TLR agonist conjugates |
| SG11202110480YA (en) | 2019-03-27 | 2021-10-28 | Merck Patent Gmbh | Imidazolonylquinoline compounds and therapeutic uses thereof |
| EP4051270A4 (en) * | 2019-10-29 | 2024-02-28 | Prime Reach Trading Limited | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF |
| WO2021116420A1 (en) | 2019-12-13 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis |
| MX2022006578A (en) | 2019-12-17 | 2022-07-04 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof. |
| WO2022013775A1 (en) | 2020-07-17 | 2022-01-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| WO2022130046A1 (en) * | 2020-12-16 | 2022-06-23 | 3M Innovative Properties Company | N-1 branched imidazoquinolines, conjugates thereof, and methods |
| WO2025104289A1 (en) | 2023-11-17 | 2025-05-22 | Medincell S.A. | Antineoplastic combinations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5444065A (en) * | 1993-07-15 | 1995-08-22 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines as inducer of interferon α biosynthesis |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2135210A (en) * | 1937-03-13 | 1938-11-01 | John R Farrar | Golf ball |
| US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| US3692907A (en) * | 1970-10-27 | 1972-09-19 | Richardson Merrell Inc | Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same |
| US3819190A (en) * | 1972-10-02 | 1974-06-25 | D Nepela | Golf ball |
| US4284276A (en) * | 1980-02-13 | 1981-08-18 | Worst Joseph C | Grooved golf ball |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| CA1271477A (en) * | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| JPH0327380Y2 (en) | 1985-05-22 | 1991-06-13 | ||
| US4880779A (en) * | 1987-07-31 | 1989-11-14 | Research Corporation Technologies, Inc. | Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
| EP0385630B1 (en) | 1989-02-27 | 1996-11-27 | Riker Laboratories, Inc. | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| US5054153A (en) * | 1989-12-01 | 1991-10-08 | Silliman Paul D | Golf club cleaner |
| ATE121088T1 (en) | 1990-10-05 | 1995-04-15 | Minnesota Mining & Mfg | METHOD FOR PRODUCING IMIDAZO(4,5- C>QUINOLINE-4-AMINES. |
| US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| JP2955019B2 (en) | 1991-03-01 | 1999-10-04 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 1-substituted, 2-substituted 1H-imidazo [4,5-c] quinolin-4-amine |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| FR2692159B1 (en) * | 1992-06-10 | 1996-10-11 | Vartan Berberian | BALL FOR BALL GAMES AND METHODS OF OBTAINING SUCH A BALL. |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| ES2149276T3 (en) | 1993-07-15 | 2000-11-01 | Minnesota Mining & Mfg | IMIDAZO (4,5-C) PIRIDIN-4-AMINAS. |
| US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| JPH09116911A (en) * | 1995-10-20 | 1997-05-02 | Canon Inc | Imaging system |
| JPH09208584A (en) | 1996-01-29 | 1997-08-12 | Terumo Corp | Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same |
| JPH09255926A (en) | 1996-03-26 | 1997-09-30 | Diatex Co Ltd | Adhesive tape |
| US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| US5759109A (en) * | 1996-09-09 | 1998-06-02 | Martini; Byron Rocco | Simulated golf ball instructional device |
| CZ294563B6 (en) * | 1996-10-25 | 2005-02-16 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of TH2 cell mediated and related diseases |
| US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| EP0894797A4 (en) * | 1997-01-09 | 2001-08-16 | Terumo Corp | Novel amide derivatives and intermediates for the synthesis thereof |
| UA67760C2 (en) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
| JPH11222432A (en) | 1998-02-03 | 1999-08-17 | Terumo Corp | Preparation for external use containing amide derivative inducing interferon |
| JPH11255926A (en) | 1998-03-13 | 1999-09-21 | Toray Ind Inc | Silicone molding and its production |
| US6239965B1 (en) * | 1998-05-22 | 2001-05-29 | Matsushita Electric Industrial Co., Ltd. | Electrolytic capacitor and method of producing the same |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2000119271A (en) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1H-imidazopyridine derivative |
| EP1495758A3 (en) | 1999-01-08 | 2005-04-13 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| HU229441B1 (en) * | 1999-01-08 | 2013-12-30 | 3M Innovative Properties Co | Formulations and methods for treating mucosal associated conditions with an immune response modifier |
| US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| JP2000247884A (en) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | Arachidonic acid-induced skin disease treatment |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US6894060B2 (en) | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
| US20020055517A1 (en) | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
| JP2002145777A (en) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | Arachidonic acid-induced skin disease treatment |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US6664265B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| CA2430206A1 (en) | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| JP2005519849A (en) | 2001-06-15 | 2005-07-07 | スリーエム イノベイティブ プロパティズ カンパニー | Immune response modifier for the treatment of periodontal disease |
| JP2005501550A (en) | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | Maturation of plasmacytoid dendritic cells using immune response modifier molecules |
| EP1478371A4 (en) | 2001-10-12 | 2007-11-07 | Univ Iowa Res Found | METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUND |
| ES2318615T3 (en) | 2001-11-16 | 2009-05-01 | Coley Pharmaceutical Group, Inc. | N- (4- (4-AMINO-2-ETIL-1H-IMIDAZO (4,5-C) QUINOLIN-1-IL) BUTIL) METHANOSULPHONAMIDE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES ITSELF. |
| NZ532769A (en) | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| EP1478327B1 (en) | 2002-02-22 | 2015-04-29 | Meda AB | Method of reducing and treating uvb-induced immunosuppression |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| WO2003101949A2 (en) | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| CA2488801A1 (en) | 2002-06-07 | 2003-12-18 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| ES2355819T3 (en) | 2002-08-15 | 2011-03-31 | 3M Innovative Properties Company | IMMUNOSTIMULATING COMPOSITIONS AND METHODS TO STIMULATE AN IMMUNE ANSWER. |
| AU2003299082A1 (en) | 2002-09-26 | 2004-04-19 | 3M Innovative Properties Company | 1h-imidazo dimers |
| AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
| AU2003287316A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
| NZ540826A (en) * | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
| WO2004060319A2 (en) | 2002-12-30 | 2004-07-22 | 3M Innovative Properties Company | Immunostimulatory combinations |
| EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
| US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
| JP2006519866A (en) | 2003-03-04 | 2006-08-31 | スリーエム イノベイティブ プロパティズ カンパニー | Prophylactic treatment of UV-induced epidermal neoplasia |
| MXPA05009488A (en) | 2003-03-07 | 2005-12-14 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines. |
| US7699057B2 (en) | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
| CA2518445A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| ATE556711T1 (en) | 2003-03-13 | 2012-05-15 | 3M Innovative Properties Co | METHOD FOR IMPROVING SKIN QUALITY |
| JP2006523452A (en) | 2003-03-25 | 2006-10-19 | スリーエム イノベイティブ プロパティズ カンパニー | Selective activation of cellular activity mediated through a common Toll-like receptor |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| AU2004244962A1 (en) | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
| US7576068B2 (en) | 2003-09-05 | 2009-08-18 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
-
2001
- 2001-06-12 UA UA2003065275A patent/UA74852C2/en unknown
- 2001-06-12 UA UA2003065277A patent/UA75622C2/en unknown
- 2001-12-06 CZ CZ20031563A patent/CZ20031563A3/en unknown
- 2001-12-06 MX MXPA03004972A patent/MXPA03004972A/en active IP Right Grant
- 2001-12-06 BR BR0116470-8A patent/BR0116470A/en not_active IP Right Cessation
- 2001-12-06 BR BRPI0116464-3A patent/BR0116464A/en not_active IP Right Cessation
- 2001-12-06 BR BRPI0116032-0A patent/BR0116032A/en not_active IP Right Cessation
- 2001-12-06 SK SK710-2003A patent/SK287264B6/en not_active IP Right Cessation
- 2001-12-06 CA CA002430844A patent/CA2430844A1/en not_active Withdrawn
- 2001-12-06 SK SK711-2003A patent/SK7112003A3/en unknown
- 2001-12-06 DK DK01992018T patent/DK1343784T3/en active
- 2001-12-06 CA CA002431151A patent/CA2431151A1/en not_active Withdrawn
- 2001-12-06 AU AU2002239517A patent/AU2002239517B2/en not_active Ceased
- 2001-12-06 EE EEP200300272A patent/EE200300272A/en unknown
- 2001-12-06 KR KR10-2003-7007537A patent/KR20030070050A/en not_active Withdrawn
- 2001-12-06 CZ CZ20031562A patent/CZ20031562A3/en unknown
- 2001-12-06 RU RU2003116061/04A patent/RU2315049C2/en not_active IP Right Cessation
- 2001-12-06 US US10/012,599 patent/US6683088B2/en not_active Expired - Fee Related
- 2001-12-06 MX MXPA03004975A patent/MXPA03004975A/en active IP Right Grant
- 2001-12-06 WO PCT/US2001/046697 patent/WO2002046192A2/en not_active Ceased
- 2001-12-06 RU RU2003116123/04A patent/RU2003116123A/en not_active Application Discontinuation
- 2001-12-06 DE DE60117859T patent/DE60117859T2/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002547930A patent/JP2004515501A/en active Pending
- 2001-12-06 EP EP01987297A patent/EP1341791B1/en not_active Expired - Lifetime
- 2001-12-06 PT PT01987283T patent/PT1341790E/en unknown
- 2001-12-06 CN CNA018201725A patent/CN1894244A/en active Pending
- 2001-12-06 DE DE60126645T patent/DE60126645T2/en not_active Expired - Fee Related
- 2001-12-06 NZ NZ526086A patent/NZ526086A/en unknown
- 2001-12-06 AT AT01987297T patent/ATE296301T1/en active
- 2001-12-06 HU HU0600600A patent/HUP0600600A2/en unknown
- 2001-12-06 CZ CZ20031591A patent/CZ20031591A3/en unknown
- 2001-12-06 AU AU2002232497A patent/AU2002232497B2/en not_active Ceased
- 2001-12-06 CN CNB01820161XA patent/CN1253452C/en not_active Expired - Fee Related
- 2001-12-06 US US10/013,202 patent/US6670372B2/en not_active Expired - Fee Related
- 2001-12-06 PL PL01365995A patent/PL365995A1/en unknown
- 2001-12-06 JP JP2002547929A patent/JP2004515500A/en not_active Withdrawn
- 2001-12-06 CZ CZ20031560A patent/CZ295848B6/en not_active IP Right Cessation
- 2001-12-06 SK SK713-2003A patent/SK287732B6/en not_active IP Right Cessation
- 2001-12-06 AU AU3061802A patent/AU3061802A/en active Pending
- 2001-12-06 PT PT01987297T patent/PT1341791E/en unknown
- 2001-12-06 EP EP01992005A patent/EP1341792A2/en not_active Withdrawn
- 2001-12-06 RU RU2003116060/04A patent/RU2302418C2/en active
- 2001-12-06 DK DK01987297T patent/DK1341791T3/en active
- 2001-12-06 KR KR10-2003-7007535A patent/KR20040028690A/en not_active Withdrawn
- 2001-12-06 RU RU2003116649/04A patent/RU2351598C2/en not_active IP Right Cessation
- 2001-12-06 HU HU0600338A patent/HUP0600338A2/en active IP Right Revival
- 2001-12-06 ES ES01987283T patent/ES2281456T3/en not_active Expired - Lifetime
- 2001-12-06 DE DE60111076T patent/DE60111076T2/en not_active Expired - Lifetime
- 2001-12-06 ES ES01992018T patent/ES2260323T3/en not_active Expired - Lifetime
- 2001-12-06 SI SI200130720T patent/SI1341790T1/en unknown
- 2001-12-06 JP JP2002547927A patent/JP2004529078A/en active Pending
- 2001-12-06 CN CNB018201679A patent/CN1297554C/en not_active Expired - Fee Related
- 2001-12-06 AU AU2002232482A patent/AU2002232482B2/en not_active Ceased
- 2001-12-06 IL IL15590401A patent/IL155904A0/en unknown
- 2001-12-06 MX MXPA03004974A patent/MXPA03004974A/en active IP Right Grant
- 2001-12-06 WO PCT/US2001/046704 patent/WO2002046193A2/en not_active Ceased
- 2001-12-06 IL IL15604301A patent/IL156043A0/en unknown
- 2001-12-06 NZ NZ526105A patent/NZ526105A/en unknown
- 2001-12-06 HR HR20030464A patent/HRP20030464A2/en not_active Application Discontinuation
- 2001-12-06 WO PCT/US2001/046582 patent/WO2002046190A2/en not_active Ceased
- 2001-12-06 BR BR0116047-8A patent/BR0116047A/en not_active IP Right Cessation
- 2001-12-06 AU AU3248202A patent/AU3248202A/en active Pending
- 2001-12-06 AT AT01987283T patent/ATE353895T1/en not_active IP Right Cessation
- 2001-12-06 HU HU0700062A patent/HUP0700062A2/en active IP Right Revival
- 2001-12-06 CN CNA018201687A patent/CN1479739A/en active Pending
- 2001-12-06 HU HU0600605A patent/HUP0600605A2/en unknown
- 2001-12-06 WO PCT/US2001/046359 patent/WO2002046188A2/en not_active Ceased
- 2001-12-06 KR KR10-2003-7007534A patent/KR20030070049A/en not_active Abandoned
- 2001-12-06 MX MXPA03005012A patent/MXPA03005012A/en active IP Right Grant
- 2001-12-06 HR HR20030461A patent/HRP20030461A2/en not_active Application Discontinuation
- 2001-12-06 MX MXPA03004973A patent/MXPA03004973A/en not_active Application Discontinuation
- 2001-12-06 CZ CZ20031592A patent/CZ303462B6/en not_active IP Right Cessation
- 2001-12-06 KR KR10-2003-7007538A patent/KR20040028691A/en not_active Withdrawn
- 2001-12-06 AU AU3951702A patent/AU3951702A/en active Pending
- 2001-12-06 JP JP2002547928A patent/JP2004521092A/en not_active Ceased
- 2001-12-06 KR KR10-2003-7007532A patent/KR20040023576A/en not_active Withdrawn
- 2001-12-06 EP EP01987283A patent/EP1341790B1/en not_active Expired - Lifetime
- 2001-12-06 AU AU2002230618A patent/AU2002230618B2/en not_active Ceased
- 2001-12-06 EE EEP200300275A patent/EE200300275A/en unknown
- 2001-12-06 AU AU3249702A patent/AU3249702A/en active Pending
- 2001-12-06 EE EEP200300268A patent/EE200300268A/en unknown
- 2001-12-06 IL IL15595001A patent/IL155950A0/en unknown
- 2001-12-06 AU AU2002239530A patent/AU2002239530B2/en not_active Ceased
- 2001-12-06 IL IL15604401A patent/IL156044A0/en unknown
- 2001-12-06 RU RU2003116059/04A patent/RU2308456C2/en not_active IP Right Cessation
- 2001-12-06 US US10/013,060 patent/US6656938B2/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002547925A patent/JP4437189B2/en not_active Expired - Fee Related
- 2001-12-06 NZ NZ526088A patent/NZ526088A/en unknown
- 2001-12-06 HR HR20030462A patent/HRP20030462A2/en not_active Application Discontinuation
- 2001-12-06 HU HU0400704A patent/HUP0400704A2/en unknown
- 2001-12-06 EP EP01990852A patent/EP1339715A2/en not_active Withdrawn
- 2001-12-06 BR BRPI0116052-4A patent/BR0116052A/en not_active Application Discontinuation
- 2001-12-06 CN CNB018201598A patent/CN1247575C/en not_active Expired - Fee Related
- 2001-12-06 PL PL392462A patent/PL392462A1/en unknown
- 2001-12-06 JP JP2002547926A patent/JP2004523498A/en active Pending
- 2001-12-06 EE EEP200300271A patent/EE200300271A/en unknown
- 2001-12-06 WO PCT/US2001/046581 patent/WO2002046189A2/en not_active Ceased
- 2001-12-06 KR KR10-2003-7007539A patent/KR20040047733A/en not_active Withdrawn
- 2001-12-06 PL PL01361948A patent/PL361948A1/en not_active Application Discontinuation
- 2001-12-06 PL PL01365907A patent/PL365907A1/en not_active Application Discontinuation
- 2001-12-06 PL PL01366115A patent/PL366115A1/en not_active Application Discontinuation
- 2001-12-06 CZ CZ20031561A patent/CZ20031561A3/en unknown
- 2001-12-06 CA CA2436980A patent/CA2436980C/en not_active Expired - Fee Related
- 2001-12-06 WO PCT/US2001/046696 patent/WO2002046191A2/en not_active Ceased
- 2001-12-06 SK SK684-2003A patent/SK6842003A3/en not_active Application Discontinuation
- 2001-12-06 BR BR0116026-5A patent/BR0116026A/en not_active IP Right Cessation
- 2001-12-06 IL IL15590301A patent/IL155903A0/en unknown
- 2001-12-06 AU AU3951602A patent/AU3951602A/en active Pending
- 2001-12-06 EP EP01992018A patent/EP1343784B1/en not_active Expired - Lifetime
- 2001-12-06 NZ NZ526087A patent/NZ526087A/en unknown
- 2001-12-06 SK SK715-2003A patent/SK7152003A3/en unknown
- 2001-12-06 AU AU2002239516A patent/AU2002239516B2/en not_active Ceased
- 2001-12-06 HR HR20030463A patent/HRP20030463A2/en not_active Application Discontinuation
- 2001-12-06 DK DK01987283T patent/DK1341790T3/en active
- 2001-12-06 PL PL366330A patent/PL207340B1/en not_active IP Right Cessation
- 2001-12-06 PL PL01365883A patent/PL365883A1/en not_active Application Discontinuation
- 2001-12-06 HR HR20030467A patent/HRP20030467B1/en not_active IP Right Cessation
- 2001-12-06 NZ NZ526106A patent/NZ526106A/en not_active IP Right Cessation
- 2001-12-06 EP EP01987282A patent/EP1341789A2/en not_active Ceased
- 2001-12-06 HU HU0400710A patent/HUP0400710A2/en unknown
- 2001-12-06 RU RU2003116063/04A patent/RU2003116063A/en not_active Application Discontinuation
- 2001-12-06 NZ NZ526089A patent/NZ526089A/en unknown
- 2001-12-06 CA CA002436983A patent/CA2436983A1/en not_active Abandoned
- 2001-12-06 EE EEP200300270A patent/EE200300270A/en unknown
- 2001-12-06 MX MXPA03005011A patent/MXPA03005011A/en active IP Right Grant
- 2001-12-06 EE EEP200300274A patent/EE200300274A/en unknown
- 2001-12-06 SK SK712-2003A patent/SK7122003A3/en unknown
- 2001-12-06 ES ES01987297T patent/ES2242782T3/en not_active Expired - Lifetime
- 2001-12-06 CA CA002436984A patent/CA2436984A1/en not_active Abandoned
- 2001-12-06 CN CNB018199070A patent/CN1252070C/en not_active Expired - Fee Related
- 2001-12-06 CA CA2436846A patent/CA2436846C/en not_active Expired - Fee Related
- 2001-12-06 IL IL15588401A patent/IL155884A0/en unknown
- 2001-12-06 AU AU3953002A patent/AU3953002A/en active Pending
- 2001-12-06 HR HR20030466A patent/HRP20030466A2/en not_active Application Discontinuation
- 2001-12-06 AT AT01992018T patent/ATE319711T1/en not_active IP Right Cessation
- 2001-12-07 TW TW090130404A patent/TWI293300B/en active
- 2001-12-07 TW TW090130401A patent/TW584633B/en not_active IP Right Cessation
- 2001-12-07 TW TW090130402A patent/TWI222972B/en active
- 2001-12-10 AR ARP010105730A patent/AR035668A1/en unknown
- 2001-12-10 AR ARP010105726A patent/AR035664A1/en active IP Right Grant
- 2001-12-10 AR ARP010105728A patent/AR035666A1/en unknown
- 2001-12-10 AR ARP010105731A patent/AR035669A1/en unknown
- 2001-12-10 AR ARP010105729A patent/AR035667A1/en unknown
- 2001-12-10 AR ARP010105727A patent/AR035665A1/en unknown
-
2003
- 2003-05-28 NO NO20032452A patent/NO20032452L/en not_active Application Discontinuation
- 2003-05-28 NO NO20032451A patent/NO20032451L/en not_active Application Discontinuation
- 2003-05-28 NO NO20032449A patent/NO20032449L/en not_active Application Discontinuation
- 2003-05-30 NO NO20032473A patent/NO326159B1/en not_active IP Right Cessation
- 2003-06-06 NO NO20032595A patent/NO20032595D0/en not_active Application Discontinuation
- 2003-06-06 NO NO20032596A patent/NO20032596D0/en not_active Application Discontinuation
- 2003-07-08 ZA ZA200305270A patent/ZA200305270B/en unknown
- 2003-07-08 ZA ZA200305271A patent/ZA200305271B/en unknown
- 2003-07-08 ZA ZA200305273A patent/ZA200305273B/en unknown
- 2003-07-08 ZA ZA200305275A patent/ZA200305275B/en unknown
- 2003-07-08 ZA ZA200305274A patent/ZA200305274B/en unknown
- 2003-07-08 ZA ZA2003/05272A patent/ZA200305272B/en unknown
- 2003-10-07 US US10/680,989 patent/US7049439B2/en not_active Expired - Fee Related
- 2003-10-29 US US10/696,476 patent/US20040092545A1/en not_active Abandoned
- 2003-10-29 US US10/696,753 patent/US6953804B2/en not_active Expired - Fee Related
-
2005
- 2005-02-28 US US11/069,033 patent/US7132429B2/en not_active Expired - Fee Related
- 2005-05-19 US US11/132,900 patent/US7612083B2/en not_active Expired - Fee Related
- 2005-08-24 CY CY20051101024T patent/CY1105586T1/en unknown
-
2007
- 2007-05-09 CY CY20071100621T patent/CY1106569T1/en unknown
-
2009
- 2009-11-06 JP JP2009255040A patent/JP2010031040A/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5444065A (en) * | 1993-07-15 | 1995-08-22 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines as inducer of interferon α biosynthesis |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1297554C (en) | Amido ether substituted imidazoquinolines | |
| CN1599740A (en) | Amide substituted imidazopyridines | |
| CN1355701A (en) | Urea substituted imidazoquinolines | |
| CN1249062C (en) | Substituted imidazopyridines | |
| CN1147493C (en) | Oxazolo and thiazolo[4,5-C]quinolin-4-amines and their analogues and pharmaceutical compositions containing them | |
| CN1154647C (en) | Imidazo 1, 5-naphthyridines and their use in eliciting cytokine biosynthesis | |
| CN1249061C (en) | Sulfonamide and sulfamide substituted imidazoquinolines | |
| CN1027265C (en) | Preparation method of water-soluble camptothecin analog | |
| CN1263756C (en) | Imidazopyrimidine Derivatives and Triazolopyrimidine Derivatives | |
| CN1674894A (en) | Ether substituted imidazopyridines | |
| CN1922178A (en) | Piperazine, [1, 4 ]diazepane ([1,4]diazepane ), [1,4 ]diazepane ([1,4]diazocane), and [1,5] diazepane Azacyclooctane ([1,5] diazocane) fused imidazo ring compound | |
| CN1812789A (en) | Sulfonamide substituted imidazoquinolines | |
| CN1353609A (en) | Amide substituted imidazoquinolines | |
| CN1897948A (en) | Alkoxy substituted imidazoquinolines | |
| CN1198827C (en) | Selected derivatives of K-252a | |
| CN1918160A (en) | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | |
| CN1377353A (en) | Purine derivatives having phosphodiesterase IN inhibition activity | |
| CN1209368C (en) | Novel acetamide derivative and use thereof | |
| CN1878750A (en) | Arylalkylcarbamate derivatives, processes for their preparation and their use in therapy | |
| CN1079744A (en) | 7-oxo-7H-pyrido [1,2,3 ,-d, e] [1,4] benzoxazine-6-carboxylic acids and ester thereof | |
| CN1256336C (en) | Novel 4'-demethyl-4'-0-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for preparation thereof and anti-cancer composition comprising same | |
| CN87105992A (en) | Pyrimidine derivatives | |
| HK1064383B (en) | Amido ether substituted imidazoquinolines | |
| HK1069166B (en) | Urea substituted imidazoquinoline ethers | |
| HK1066005B (en) | Sulfonamido ether substituted imidazoquinolines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1064383 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070131 Termination date: 20171206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |